<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80014</article-id><article-id pub-id-type="doi">10.7554/eLife.80014</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Phosphoproteomic mapping reveals distinct signaling actions and activation of muscle protein synthesis by Isthmin-1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-280474"><name><surname>Zhao</surname><given-names>Meng</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5415-8335</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280476"><name><surname>Banhos Danneskiold-Samsøe</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-280484"><name><surname>Ulicna</surname><given-names>Livia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280477"><name><surname>Nguyen</surname><given-names>Quennie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244186"><name><surname>Voilquin</surname><given-names>Laetitia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2138-4819</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280478"><name><surname>Lee</surname><given-names>David E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-280479"><name><surname>White</surname><given-names>James P</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-280480"><name><surname>Jiang</surname><given-names>Zewen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3852-8666</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-280481"><name><surname>Cuthbert</surname><given-names>Nickeisha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-280482"><name><surname>Paramasivam</surname><given-names>Shrika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-219785"><name><surname>Bielczyk-Maczynska</surname><given-names>Ewa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0558-1188</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-280483"><name><surname>Van Rechem</surname><given-names>Capucine</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5408-6124</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-278818"><name><surname>Svensson</surname><given-names>Katrin J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5376-5128</contrib-id><email>katrinjs@stanford.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Department of Pathology, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford Diabetes Research Center, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford Cardiovascular Institute, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Duke Molecular Physiology Institute, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Department of Medicine, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Duke Center for the Study of Aging and Human Development, Duke University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Durham</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Laboratory Medicine, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Diabetes Center, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>28</day><month>09</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e80014</elocation-id><history><date date-type="received" iso-8601-date="2022-05-05"><day>05</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-27"><day>27</day><month>09</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-05-25"><day>25</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.19.492758"/></event></pub-history><permissions><copyright-statement>© 2022, Zhao et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Zhao et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80014-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-80014-figures-v2.pdf"/><abstract><p>The secreted protein isthmin-1 (Ism1) mitigates diabetes by increasing adipocyte and skeletal muscle glucose uptake by activating the PI3K-Akt pathway. However, while both Ism1 and insulin converge on these common targets, Ism1 has distinct cellular actions suggesting divergence in downstream intracellular signaling pathways. To understand the biological complexity of Ism1 signaling, we performed phosphoproteomic analysis after acute exposure, revealing overlapping and distinct pathways of Ism1 and insulin. We identify a 53% overlap between Ism1 and insulin signaling and Ism1-mediated phosphoproteome-wide alterations in ~450 proteins that are not shared with insulin. Interestingly, we find several unknown phosphorylation sites on proteins related to protein translation, mTOR pathway, and, unexpectedly, muscle function in the Ism1 signaling network. Physiologically, <italic>Ism1</italic> ablation in mice results in altered proteostasis, including lower muscle protein levels under fed and fasted conditions, reduced amino acid incorporation into proteins, and reduced phosphorylation of the key protein synthesis effectors Akt and downstream mTORC1 targets. As metabolic disorders such as diabetes are associated with accelerated loss of skeletal muscle protein content, these studies define a non-canonical mechanism by which this antidiabetic circulating protein controls muscle biology.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Cells need energy to survive and carry out their role in the body. They do this by breaking down molecules, like sugar, into substances that can fuel the creation of new compounds, like proteins or lipids. This process, known as metabolism, involves a series of interconnecting chemical reactions which are organized into pathways.</p><p>Metabolic pathways contain proteins that catalyze each sequential reaction. Hormones can change the activity of these proteins by adding a chemical group called a phosphate. This reversible modification can majorly impact the metabolism of cells, resulting in changes to the body’s tissues. The hormone insulin, for instance, alters a well-known metabolic pathway that triggers skeletal muscle cells to produce more proteins, leading to stronger and larger muscles.</p><p>In 2021, a group of scientists discovered a molecule made by fat cells, called Isthmin-1, also activates components in this pathway. Similar to insulin, Isthmin-1 encourages muscle and fat cells to take up sugar. However, it also prevents the liver from accumulating excess fat, suggesting Isthmin-1 may trigger a different cascade of molecules to insulin.</p><p>To investigate this possibility, Zhao et al. – including some of the researchers involved in the 2021 study – exposed cells grown in the laboratory to Isthmin-1 or insulin and looked for phosphates on all their proteins. This revealed that only 53% of the proteins Isthmin-1 modifies are also altered by insulin. Of the proteins unique to Isthmin-1, several had known roles in making and maintaining proteins in muscle cells.</p><p>To understand more about the role of this newly discovered pathway, Zhao et al. genetically engineered mice to lack the gene that codes for Isthmin-1. This decreased the size and strength of the mice’s muscle fibers and reduced the signals that normally lead to skeletal muscle growth.</p><p>These findings suggest that Isthmin-1 regulates skeletal muscle size via a metabolic pathway that is slightly different to the one activated by insulin. Many metabolic disorders are associated with muscle loss, like diabetes, and this newly discovered network of proteins could further our understanding of how to prevent and treat these diseases.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>proteomics</kwd><kwd>signaling</kwd><kwd>muscle</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK125260</award-id><principal-award-recipient><name><surname>Svensson</surname><given-names>Katrin J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK111916</award-id><principal-award-recipient><name><surname>Svensson</surname><given-names>Katrin J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>905674</award-id><principal-award-recipient><name><surname>Zhao</surname><given-names>Meng</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>18POST34030448</award-id><principal-award-recipient><name><surname>Bielczyk-Maczynska</surname><given-names>Ewa</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>T32HL007057</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>David E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>882082</award-id><principal-award-recipient><name><surname>Cuthbert</surname><given-names>Nickeisha</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>DK116074</award-id><principal-award-recipient><name><surname>Svensson</surname><given-names>Katrin J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R21AG065943</award-id><principal-award-recipient><name><surname>White</surname><given-names>James P</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>K01AG05666</award-id><principal-award-recipient><name><surname>White</surname><given-names>James P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The role of Isthmin-1 in muscle function is defined by using phosphoproteomics to identify distinct and overlapping signaling pathways between Isthmin-1 and insulin.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hormonal signaling through protein phosphorylation is one of the most important post-translational modifications allowing for rapid changes in cellular metabolic states (<xref ref-type="bibr" rid="bib23">Humphrey et al., 2015</xref>). Metabolic stressors such as diabetes or fasting can lead to pronounced physiological and cellular adaptations in protein regulation (<xref ref-type="bibr" rid="bib53">Powers et al., 2009</xref>). Consequently, pathological conditions can result in muscle atrophy, a net loss of muscle mass, which is highly associated with morbidity (<xref ref-type="bibr" rid="bib11">Cohen et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Jackman and Kandarian, 2004</xref>). Muscle strength is reduced in individuals with insulin resistance and type 2 diabetes (<xref ref-type="bibr" rid="bib2">Andersen et al., 2004</xref>; <xref ref-type="bibr" rid="bib49">Park et al., 2007</xref>), and muscle weakness is even a diagnostic predictor of diabetes (<xref ref-type="bibr" rid="bib52">Peterson et al., 2016</xref>). The mechanisms underlying this association have remained elusive, but it is plausible that factors derived from adipose tissue can contribute to muscle proteostasis. Identifying such molecular triggers of muscle metabolism could facilitate our efforts to develop pharmacological agents that improve muscle function and systemic metabolic health.</p><p>Skeletal muscle is the most abundant tissue in humans, representing up to half of the total mass in normal-weight individuals (<xref ref-type="bibr" rid="bib27">Janssen et al., 2000</xref>). As a major organ for glycogen storage and insulin-mediated glucose uptake, skeletal muscle controls whole-body energy expenditure and nutrient homeostasis (<xref ref-type="bibr" rid="bib13">Deshmukh, 2016</xref>; <xref ref-type="bibr" rid="bib63">Shulman et al., 1990</xref>). Importantly, skeletal muscle also acts as a protein reservoir that is highly responsive to anabolic or catabolic hormonal stimulation, including growth hormone (GH) and insulin-like growth factor-1 (IGF-1), both of which stimulate muscle fiber size (hypertrophy) (<xref ref-type="bibr" rid="bib43">Moro et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Velloso, 2008</xref>). Muscle mass is balanced by pathways controlling protein synthesis and protein degradation. The most well-described anabolic signaling pathway that promotes protein synthesis requires Akt/mTORC1 signaling, which robustly induces muscle hypertrophy upon stimulation by growth factors or amino acids (<xref ref-type="bibr" rid="bib5">Bodine et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Glass, 2011</xref>; <xref ref-type="bibr" rid="bib30">Lai et al., 2004</xref>). In both flies (<xref ref-type="bibr" rid="bib60">Scanga et al., 2000</xref>) and mammals (<xref ref-type="bibr" rid="bib14">Edinger and Thompson, 2002</xref>), the PI3K-Akt pathway controls cell size by increasing protein synthesis at the level of translation initiation. Akt also inhibits the catabolic function of FoxO family members, which upon phosphorylation are no longer able to enter the nucleus and turn on the transcription of atrophy genes, including the E3 ubiquitin ligases MuRF1 and atrogin-1 (<xref ref-type="bibr" rid="bib5">Bodine et al., 2001</xref>; <xref ref-type="bibr" rid="bib6">Bodine and Baehr, 2014</xref>; <xref ref-type="bibr" rid="bib17">Gomes et al., 2001</xref>; <xref ref-type="bibr" rid="bib34">Lecker et al., 1999</xref>).</p><p>We recently reported that the adipocyte-secreted protein isthmin-1 (Ism1) improves glucose tolerance and insulin resistance by phosphorylating Akt<sup>S473</sup>, which mediates increased adipose and skeletal muscle glucose uptake (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). <italic>Ism1</italic> adipose expression and circulating levels are elevated in mice and humans with obesity (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Ruiz-Ojeda et al., 2022</xref>), suggesting that the expression is under nutrient-sensing regulatory control. Intriguingly, Ism1 administration to mice simultaneously prevents hepatic lipid accumulation while increasing protein synthesis in hepatocytes (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>), demonstrating that Ism1 governs an anabolic pathway that is molecularly and functionally distinct from insulin. In this study, we find that Ism1 induces specific Ism1-regulated phosphoproteome changes enriched for proteins controlling protein translation, mTOR signaling, and muscle function. Furthermore, we show that Ism1 is important to maintain skeletal muscle fiber size under fasting, thereby defining a non-canonical mechanism by which Ism1 controls muscle biology.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Phosphoproteomics reveals overlapping and distinct pathways of Ism1 and insulin</title><p>The PI3K-Akt pathway is a key pathway of convergence for ligands that activate receptor tyrosine kinases (RTKs), including insulin (<xref ref-type="bibr" rid="bib22">Humphrey et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Luo et al., 2003</xref>; <xref ref-type="bibr" rid="bib77">Zhao et al., 2020</xref>). We recently identified Ism1 as an adipose-secreted protein that increases glucose uptake into fat and muscle by potently activating PI3K-Akt signaling across a range of mouse and human cell types, but unlike insulin, does not induce de novo lipogenesis (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). Therefore, the extent to which the entire Ism1-signaling network overlaps with insulin or whether other signaling nodes are involved remains to be determined. Therefore, to increase our understanding of the signaling divergence and obtain an unbiased, more complete view of the Ism1-induced signaling network, we performed phosphoproteomics in the Ism1 and insulin-responsive 3T3-F442A cells. To characterize the Ism1-induced phospho-signaling profile after acute treatment in cells, we used phosphopeptide enrichment with TiO<sub>2</sub> followed by LC-MS/MS using Orbitrap Elite (<xref ref-type="bibr" rid="bib74">Yue et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Zhou et al., 2008</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Cells were starved overnight, followed by a 5 min treatment with 100 nM recombinant Ism1, or 100 nM insulin. As a negative control, bovine serum albumin (BSA), a secreted protein in the same size range as Ism1, was used at 100 nM. Although pAkt <sup>S473</sup> induction was more pronounced by insulin, we observed robust activation of pAkt <sup>S473</sup> 5 min post-treatment with Ism1, and therefore selected this time point for our analysis (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). The proteomic experiments were performed in treatment groups of six biological replicates, after which the pooled cells were divided into two technical replicates for the proteomics analysis. In total, ~7700 raw MS precursor ions (peptides) were acquired, resulting in the identification of unique phosphopeptides on &gt;5000 proteins (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). Principal component analysis (PCA) demonstrates high reproducibility between biological replicates and distinct separation of the Ism1- and insulin-treated groups compared with each other and the albumin control (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Interestingly, we identify overlapping and distinct Ism1 and insulin-specific phosphoproteome-wide alterations upon acute stimulation, with BSA as control. There is a 53% overlap between Ism1 and insulin signaling (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Insulin induces phosphorylation of 654 phosphosites, out of which 347 phosphosites are also phosphorylated or dephosphorylated by Ism1 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Phosphoproteomics reveals overlapping and distinct pathways of Ism1 and insulin.</title><p>(<bold>A</bold>) Experimental design of the untargeted phosphoproteomics analysis. 3T3-F442A cells were serum-starved for 16 hr and treated with 100 nM recombinant Ism1 or insulin for 5 min (n = 6 biological replicates per group were pooled and then divided into n = 2 technical replicates). Proteins were extracted, trypsin digested, and fractionated. Phosphopeptides were enriched using TiO<sub>2</sub> chromatography, and phosphopeptides were analyzed with LC-MS/MS. (<bold>B</bold>) Western blot analysis of p-AKT<sup>S473</sup>, total AKT, and β-actin in cells treated with 100 nM bovine serum albumin (BSA), 100 nM Ism1, or 100 nM insulin for 5 min (Western blot n = 2 pooled from n = 6 per treatment group; quantification n = 4 combining three independent assays). p-Values are calculated by one-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***<italic>P</italic>p0.001. (<bold>C</bold>) Protein intensity-based principal component analysis (PCA) of the phosphoproteomic dataset. (<bold>D</bold>) Venn diagram of the phosphopeptides detected in both replicates after BSA-, Ism1-, or insulin treatment. (<bold>E</bold>) Heatmap of differentially phosphorylated peptides with 100 lowest significant p-values (adj. p&lt;0.05) from three comparisons displayed as log2 ratio (BSA vs. Ism1, BSA vs. insulin, and insulin vs. Ism1). (<bold>F</bold>) Distribution diagram of shared and unique phosphosites (detected in at least one sample) between treatments for selected Gene Ontology (GO) pathways. Inner links in shades show phosphosites detected in two or more treatment conditions. Gray shows phosphosites detected in all samples; purple shows phosphosites detected in both Ism1 and insulin-treated cells; green shows phosphosites detected in both BSA and insulin-treated cells; blue shows phosphosites detected in both BSA- and Ism1-treated cells. The middle ring displays GO pathway/pathway group with ticks indicating the number of phosphopeptides. Large ticks indicate 50 phosphopeptides, and small ticks indicate 5 phosphopeptides. The outer ring displays gene symbols and the phosphosite exclusively detected in each treatment. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>, and <xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>List of phosphosites significantly different between treatments for <xref ref-type="fig" rid="fig1">Figure 1E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>List of shared and unique phosphosites between treatments for selected Gene Ontology (GO) pathways for <xref ref-type="fig" rid="fig1">Figure 1F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig1-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Uncropped Western blot images with relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80014-fig1-data3-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Quality controls for the phosphoproteomics analysis.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Remarkably, Ism1 causes changes in the phosphorylation status of 445 proteins compared with BSA that are not shared with insulin and not previously described (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Groupwise comparisons between treatments show phosphosites selectively regulated by the specific ligands (adj. p-value of &lt;0.05), many of which have not previously been identified (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Based on the notion that Ism1 causes alterations in phosphorylation of a subset of proteins, while another subset is shared with insulin, we next used Gene Ontology (GO) analysis to discern cellular signaling pathways associated with Ism1 or insulin. While Ism1 and insulin share the majority of phosphopeptides for detected genes annotated to these GO terms, some phosphorylated residues could only be identified in one condition (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Furthermore, we analyzed to which extent the phosphorylation patterns overlapped between the Ism1 and insulin for genes belonging to the GO terms ‘GO:0008286, insulin receptor signaling,’ ‘GO:0038201, TOR complex,’ and GO terms including the word ‘muscle’ (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Interestingly, we find that Ism1 exclusively alters the phosphorylation status of proteins involved in the mTOR complex and muscle (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). These overlapping and distinct signaling nodes may reflect the signaling networks underlying the cell-specific responses.</p></sec><sec id="s2-2"><title>Phospho-specific mapping identifies an Ism1-induced signature consistent with protein translation and muscle function</title><p>To interrogate the Ism1-specific signal transduction pathway in more detail, we compared the overlapping phosphopeptides clustered by functional GO pathway groups. Expectedly, insulin induces robust phosphorylation of a subset of proteins, including the insulin receptor (IR). This phosphoproteomic mapping shows that Ism1 does not induce the exact same targets in the insulin pathway as insulin (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), which is entirely consistent with our previous study using phospho-tyrosine antibodies for the IR (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). For example, only insulin phosphorylates the InsR at Y1175/Y1163 while no significant phosphorylation is induced by Ism1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Interestingly, Ism1 induces phosphorylation of some of the same proteins as insulin, including IR substrates Irs1 and Irs2, but with distinct phosphosite patterns. For example, Irs2 was phosphorylated at T347 by insulin but at S588 by Ism1 (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Therefore, Ism1 and insulin activate overlapping but distinct pathways, which may account for some of the phenotypic and cell type-specific functions of Ism1. Similar clustering for the mTOR and muscle pathways (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>) revealed several proteins regulated only by insulin or only by Ism1. Insulin induces phosphorylation of ribosomal protein S6 (Rps6), a regulator of protein synthesis downstream of mTOR (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>), while Ism1 inhibits Rps6<sup>S236</sup> and Rps6<sup>S240</sup> phosphorylation (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). While the function of these specific phosphosites of Rps6 is understudied, our data suggest a direct regulation of mTOR activity, potentially functionally distinct from insulin. Furthermore, Ism1 induced phosphorylation of several proteins shown to regulate muscle growth and fiber size, such as adenomatous polyposis coli (Apc)<sup>S1040</sup>(<xref ref-type="bibr" rid="bib10">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Parisi et al., 2015</xref>; <xref ref-type="fig" rid="fig2">Figure 2G</xref>), supervillin (Svil)<sup>S220</sup> (<xref ref-type="bibr" rid="bib19">Hedberg-Oldfors et al., 2020</xref>; <xref ref-type="fig" rid="fig2">Figure 2H</xref>)<italic>,</italic> and FGF-receptor substrate 2 (Frs2)<sup>S327</sup> (<xref ref-type="bibr" rid="bib9">Chen and Friesel, 2009</xref>; <xref ref-type="fig" rid="fig2">Figure 2I</xref>). Frs2 is also a lipid-anchored adapter protein and downstream mediator of signaling of multiple RTKs supporting the existence of a distinct Ism1 receptor (<xref ref-type="bibr" rid="bib79">Zhou et al., 2009</xref>). As protein translation is a critical downstream target of mTOR and functionally controls muscle growth, we next investigated the regulation of ribosomal targets that catalyze protein synthesis. Interestingly, eukaryotic translation initiation factor 3 subunit A (Eif3), a complex-subunit playing a major role in translation initiation (<xref ref-type="bibr" rid="bib38">Ma et al., 2022</xref>), was phosphorylated by insulin but not Ism1 (<xref ref-type="fig" rid="fig2">Figure 2J</xref>), while 60S ribosomal protein L12 (Rpl13) at S77 (<xref ref-type="fig" rid="fig2">Figure 2K</xref>) and 40S ribosomal protein S13-1 (Rps13a) at S237 (<xref ref-type="fig" rid="fig2">Figure 2L</xref>) and Rps3a at S238 (<xref ref-type="fig" rid="fig2">Figure 2M</xref>) were entirely dephosphorylated by both Ism1 and insulin. Lastly, ribosomal protein S6 kinase alpha-5 (Rps6ka5), a known mTOR substrate (<xref ref-type="bibr" rid="bib8">Chauvin et al., 2014</xref>). was phosphorylated by both Ism1 and insulin at S375 (<xref ref-type="fig" rid="fig2">Figure 2N</xref>). These data conclude that Ism1 induces phosphorylation of a specific set of proteins involved in mTOR signaling and proteostasis, while other phosphosites are unchanged (<xref ref-type="fig" rid="fig2">Figure 2O</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Phospho-specific mapping identifies an Ism1-induced signature consistent with protein translation and muscle function.</title><p>(<bold>A</bold>) Venn diagram of shared and unique phosphosites between treatments for the Gene Ontology (GO) pathways Insulin. (<bold>B</bold>) Abundance of InsR Y1175/1163 in cells treated with bovine serum albumin (BSA), Ism1, or insulin (n = 2). Individual comparisons between conditions across phosphopeptides were performed using empirical Bayes statistics followed by adjustment for multiple testing using false discovery rate, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. The minimum normalized intensity across the dataset was subtracted from each normalized data point, and phosphorylation was calculated as a fraction of the maximum value of all samples for each phosphopeptide. Bars show mean ± SEM. (<bold>C</bold>) Venn diagram of shared and unique phosphosites between treatments for the GO pathways Insulin mTOR. (<bold>D</bold>) Venn diagram of shared and unique phosphosites between treatments for the GO pathways and muscle. (<bold>E–N</bold>) Abundance of proteins with indicated phosphosite in cells treated with BSA, Ism1, or insulin (n = 2). Individual comparisons between conditions across phosphopeptides were performed using empirical Bayes statistics followed by adjustment for multiple testing using false discovery rate, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. The minimum normalized intensity across the dataset was subtracted from each normalized data point, and phosphorylation was calculated as a fraction of the maximum value of all samples for each phosphopeptide. Note that, in case of non-detectable phosphopeptides, significance testing was based on imputed values, n.d., non-detectable. Bars show mean ± SEM. (<bold>O</bold>) Ism1 signaling network in 3T3-F442A cells. Ism1 ligand stimulation triggers activation of the PI3K/AKT pathway and the mTORC1 pathway, which leads to changes in phosphorylation status of multiple proteins involved in protein translation and muscle function. (<bold>P</bold>) Pathway analysis of enriched GO pathways in the Ism1 group versus BSA. Clusters are dominated by (1) mixed terms, (2) metabolic process, (3) development, and (4) localization/transport. Plotted GO terms all have p-values &lt;0.01 calculated using the classic Kolmogorov–Smirnov test. See also <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>, and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Enriched pathways for proteins with phosphosites significantly different between Ism1 and bovine serum albumin (BSA) clustered by semantic similarity.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig2-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Raw data related to <xref ref-type="fig" rid="fig2">Figure 2B,E–N</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig2-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Insulin receptor substrate-1 and 2 (Irs1/2) phosphorylation status in response to Ism1 or insulin.</title><p>(<bold>A</bold>) Heatmap of differentially phosphorylated Irs1 and Irs2 phosphosites by Ism1 relative to insulin (n = 2, individual comparisons between conditions across phosphopeptides using empirical Bayes statistics followed by adjustment for multiple testing using false discovery rate, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To globally discern possible pathways activated by Ism1 and possible grouping of functional effects, we conducted GO enrichment analysis using biological processes coupled with visualization by semantic similarity. We found associations previously linked to Ism1, including metabolic processes such as glucose and lipid metabolism (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Ruiz-Ojeda et al., 2022</xref>), nervous system development (<xref ref-type="bibr" rid="bib46">Osório et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Pera et al., 2002</xref>), and the immune system (<xref ref-type="bibr" rid="bib31">Lam et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib67">Valle-Rios et al., 2014</xref>; <xref ref-type="bibr" rid="bib72">Wu et al., 2021</xref>; <xref ref-type="fig" rid="fig2">Figure 2P</xref>). Intriguingly, also here, we identify several pathways associated with muscle, skeletal muscle, and cardiac muscle in the Ism1 treatment group (<xref ref-type="fig" rid="fig2">Figure 2P</xref>). These results show a broad regulation of signatures indicating a role for Ism1 in muscle function.</p></sec><sec id="s2-3"><title>Ism1 induces mTOR-dependent protein synthesis in muscle cells</title><p>Given the Ism1-induced muscle-signaling signature in 3T3-F442A cells and that the PI3K-Akt pathway is known to promote anabolic programs in muscle cells (<xref ref-type="bibr" rid="bib14">Edinger and Thompson, 2002</xref>), muscle cell differentiation (<xref ref-type="bibr" rid="bib70">Wilson and Rotwein, 2007</xref>), and skeletal muscle hypertrophy (<xref ref-type="bibr" rid="bib5">Bodine et al., 2001</xref>; <xref ref-type="bibr" rid="bib25">Jaiswal et al., 2019</xref>), we next asked whether Ism1 induces anabolic cellular signaling pathways in muscle cells. In differentiated C2C12 myotubes, Ism1 induces phosphorylation of Akt<sup>S473</sup> and ribosomal S6<sup>S235/S236</sup> starting at 5 min and remaining up to 4 hr (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The effect of Ism1 on Akt signaling is robust but lower than that of the skeletal muscle hypertrophy hormone insulin-like growth factor-1 (Igf1) (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). Similarly, undifferentiated C2C12 myoblasts are also responsive to Ism1 in a dose-dependent manner (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Notably, Ism1 treatment induced a 2.5-fold increase in protein synthesis as determined by [<sup>35</sup>S]-methionine incorporation into proteins (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). As expected, Igf1 treatment resulted in a threefold induction in protein synthesis (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), and the combined Igf1 and Ism1 treatment did not induce protein synthesis further, suggesting that the maximal capacity of protein synthesis has been reached under these conditions. Previous data showed that mTORC1/2 inhibition with rapamycin inhibits Ism1-induced signaling in 3T3-F442A cells, demonstrating that intact mTOR activity is required for the signaling capacity of Ism1 (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). Importantly, low-dose rapamycin also inhibits Ism1-induced protein synthesis, establishing that the functional effects are directly linked to the signaling cascade induced by Ism1 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). These data align with the inhibitory effects of rapamycin on muscle hypertrophy during anabolic conditions (<xref ref-type="bibr" rid="bib47">Pallafacchina et al., 2002</xref>). In conclusion, Ism1 induces a signaling cascade that requires intact mTOR signaling to induce protein synthesis in muscle cells.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Ism1 induces mTOR-dependent protein synthesis in muscle cells.</title><p>(<bold>A</bold>) Western blot analysis of p-AKT<sup>S473</sup>, total AKT, p-S6<sup>S235/</sup>236, total S6, and β-actin in C2C12 myotubes treated with 100 nM bovine serum albumin (BSA), 100 nM Ism1, or 50 ng/ml Igf1. (<bold>B</bold>) Quantification of protein expression of p-AKT S473/β-actin and p-S6 S235/236/β-actin. (<bold>C</bold>) Western blot analysis of p-AKT<sup>S473</sup>, total AKT, and β-actin in C2C12 myoblasts treated with indicated concentrations of BSA, Ism1, or Igf1 for 5 min. (<bold>D</bold>) Levels of protein synthesis measured by [<sup>35</sup>S]-methionine incorporation in C2C12 myotubes after 48 hr of indicated treatments (n = 3, one-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>E</bold>) Levels of protein synthesis measured by [<sup>35</sup>S]-methionine incorporation in C2C12 myotubes with indicated treatments for 2 hr in the presence or absence of 100 nM of the mTOR inhibitor rapamycin (n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Bar graphs show mean ± SEM. See also <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data related to <xref ref-type="fig" rid="fig3">Figure 3B, D, and E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig3-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Uncropped Western blot images with relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80014-fig3-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig3-v2.tif"/></fig></sec><sec id="s2-4"><title><italic>Ism1</italic> ablation results in reduced skeletal muscle fiber size and muscle strength</title><p>Skeletal muscle atrophy, a reduction in muscle mass, occurs when the protein degradation rate exceeds protein synthesis (<xref ref-type="bibr" rid="bib11">Cohen et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Jaiswal et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Sandri et al., 2004</xref>). We previously showed that Ism1 controls glucose uptake into adipose tissue and skeletal muscle in mice (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>), but the role of Ism1 in skeletal muscle function beyond glucose regulation has not been studied. Ism1 is broadly expressed, including highly in adipose tissue and blood (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). By analyzing single-cell RNA sequencing data from murine skeletal muscle (<xref ref-type="bibr" rid="bib3">Baht et al., 2020</xref>), we find that <italic>Ism1</italic> is not expressed in muscle precursors or mature muscle cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Given the observed signaling action of Ism1 on muscle cells, this indicated a non-cell-autonomous effect of Ism1 on muscle cells in a physiological setting. Therefore, we next sought to determine whether whole-body ablation of <italic>Ism1</italic> in mice, in which blood levels of Ism1 are completely ablated (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>), resulted in changes to skeletal muscle mass. To evaluate muscle atrophy, 8-week-old WT and <italic>Ism1</italic>-KO mice were either fasted for 12 hr or fasted followed by a 12 hr re-feeding period (fed state) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). As expected, at dissection, all fasted mice had a reduction in body weight compared with fed mice (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Blood glucose levels were 150 mg/dl in the fed state, and &lt;80 mg/dl in the fasted state (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), but no differences were seen between genotypes. Under the same conditions, quadriceps (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), gastrocnemius (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), soleus (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), as well as tibialis (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>) muscles were harvested from mice under fed or fasted states and analyzed for muscle fiber size. Muscle tissue morphology was similar between the genotypes, but the muscle fiber size was notably smaller in the <italic>Ism1</italic>-KO quadriceps muscles (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Remarkably, fiber size area quantifications showed that the <italic>Ism1</italic>-KO quadriceps muscles demonstrate a robust shift in distribution to smaller muscle fiber size areas under both fed and fasted conditions (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). On average, loss of <italic>Ism1</italic> significantly reduces the cross-sectional area by 40% in the fed state and &gt;20% in the fasted state (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Given that the Ism1 phenotype was more pronounced under the fed state, we next evaluated the effect of <italic>Ism1</italic> ablation on muscle function. While the heart weights (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), muscle weights (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), femur length (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), or total body weights (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) of <italic>Ism1</italic>-KO mice were not significantly different from WT, the <italic>Ism1</italic>-KO mice had impaired muscle force (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). In conclusion, these results show that <italic>Ism1</italic> ablation leads to smaller skeletal muscle fiber size and loss of muscle strength.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>Ism1</italic> ablation results in reduced skeletal muscle fiber size and muscle strength.</title><p>(<bold>A</bold>) Schematic description of the fasting and feeding protocol. (<bold>B</bold>) Body weights of WT and <italic>Ism1</italic>-KO mice in the fed or fasted groups (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA). (<bold>C</bold>) Blood glucose level in fed and fasted mice before dissection (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>D</bold>) Immunolabeling of laminin (red), staining of nucleus (blue) of mouse quadriceps muscles from WT and <italic>Ism1</italic>-KO mice in the fed or fasted groups (scale bars: 10 μm). Images are representative examples of three mice showing similar results. (<bold>E</bold>) Fiber size distribution of mouse quad muscles (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3). Mean percentage of myofibers within the indicated range is shown. (<bold>F</bold>) Quantification of average muscle fiber area (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, one muscle tissue per mouse, 2–4 images per muscle tissue,~60–100 myofibers quantified per image; two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001) performed in a blinded fashion by two independent investigators. This experiment was repeated using two independent cohorts of mice. (<bold>G</bold>) Grip strength measured by two-paw muscle force (<bold>N</bold>) on a grid in WT and <italic>Ism1</italic>-KO mice (WT, n = 15; <italic>Ism1</italic>-KO, n = 15). p-Values are calculated by two-tailed Student’s <italic>t</italic>-test, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Bar graphs show mean ± SEM. See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplements 1</xref> and <xref ref-type="fig" rid="fig4s2">2</xref> and <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data related to <xref ref-type="fig" rid="fig4">Figure 4B, C,E–G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Ism1 acts non-cell-autonomously on muscle cells.</title><p>(<bold>A</bold>) UMAP plot of single-cell RNA sequencing of isolated cells from mouse skeletal muscle. (<bold>B</bold>) Expression of <italic>Pdgfra</italic> in fibro-adipose precursors within the muscle. (<bold>C</bold>) Low expression of <italic>Ism1</italic> within the muscle tissue. (<bold>D</bold>) Low expression of <italic>Ism1</italic> in myocytes and myoblasts.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title><italic>Ism1</italic> ablation does not reduce muscle mass or muscle fiber size in all tissue locations.</title><p>(<bold>A</bold>) Hematoxylin and eosin (H&amp;E) staining of mouse quadriceps muscles from WT and <italic>Ism1</italic>-KO mice in the fed or fasted groups (scale bars: 50 μm). Images are representative examples of three mice showing similar results. (<bold>B–D</bold>) Quantification of average muscle fiber area in gastrocnemius (<bold>B</bold>) tibialis (<bold>C</bold>), and soleus (<bold>D</bold>) in a blinded fashion by two independent investigators (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3, WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>E</bold>) Heart mass of WT and <italic>Ism1</italic>-KO mice in the fed or fasted groups (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA). (<bold>F–H</bold>) Muscle masses of gastrocnemius (<bold>F</bold>), tibialis (<bold>G</bold>), soleus (<bold>H</bold>), and quadriceps (<bold>I</bold>) of WT and <italic>Ism1</italic>-KO mice in the fed or fasted groups (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA). (<bold>J</bold>) Femur length measured in WT and <italic>Ism1</italic>-KO (WT, n = 6; <italic>Ism1</italic>-KO, n = 5, two-tailed Student’s <italic>t</italic>-test *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Bar graphs show mean ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig4-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>Ism1 ablation does not impair movement or mitochondrial biogenesis, or normal muscle development</title><p>Since <italic>Ism1</italic> ablation causes severe myofiber atrophy, we next investigated whether loss of <italic>Ism1</italic> is associated with a reduction in movement or muscle mitochondrial complex-dependent mitochondrial bioenergetics, as has been demonstrated for IR and IGF-1R (<xref ref-type="bibr" rid="bib4">Bhardwaj et al., 2021</xref>). Ambulatory activity (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), respiratory exchange ratio (RER) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), energy expenditure as measured by VO<sub>2</sub> consumption (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), or food intake (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) are indistinguishable between WT and <italic>Ism1</italic>-KO mice when measured over a 48 hr period. Furthermore, protein levels of the mitochondrial complexes under fed and fasted conditions show no significant differences in any of the mitochondrial OXPHOS complexes I, II, III, IV, or V (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>). These data are consistent with the notion that the expression of the canonical regulator of mitochondrial biogenesis, <italic>Ppargc1a</italic> (<italic>Pgc1α</italic>) (<xref ref-type="bibr" rid="bib36">Lin et al., 2002</xref>; <xref ref-type="bibr" rid="bib71">Wu et al., 1999</xref>), is unchanged in quadriceps muscle tissues from the <italic>Ism1</italic>-KO mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). General muscle markers, including the myosin heavy chain proteins <italic>Myh1</italic>, <italic>Myh2</italic>, <italic>Myh4</italic>, and <italic>Myh7,</italic> were not altered under fed conditions, and only <italic>Myh4</italic> was reduced in the <italic>Ism1</italic>-KO mice under fasted conditions, suggesting that muscle fiber type is largely unaffected by Ism1 ablation (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). Taken together, these data suggest that Ism1 regulates muscle fiber size and muscle strength without affecting the expression of mitochondrial complexes or whole-body energy expenditure.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>Ism1</italic> ablation does not impair movement, mitochondrial biogenesis, or normal muscle development.</title><p>(<bold>A</bold>) Ambulatory activity (WT, n = 4; <italic>Ism1</italic>-KO, n = 4, ANOVA, *p&lt;0.05). (<bold>B</bold>) Respiratory exchange ratio (RER) (WT, n = 4; <italic>Ism1</italic>-KO, n = 4, ANOVA, *p&lt;0.05). (<bold>C</bold>) Oxygen consumption (WT, n = 4; <italic>Ism1</italic>-KO, n = 4, ANCOVA, *p&lt;0.05). (<bold>D</bold>) Food intake (WT, n = 4; <italic>Ism1</italic>-KO, n = 4, ANCOVA, *p&lt;0.05) in WT and Ism1-KO mice. Mice were habituated for 24 hr followed by 48 hr recordings of metabolic parameters. (<bold>E</bold>) Levels of mitochondrial oxidative phosphorylation proteins in ETC complexes (OXPHOS) from quadriceps muscles (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3; WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3) analyzed by Western blot. (<bold>F</bold>) Quantification of OXPHOS complexes (two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>G</bold>) Relative gene expression analysis of <italic>Pgc1</italic>α in quadriceps muscle from WT (n = 6) or <italic>Ism1</italic>-KO (n = 5) mice (two-tailed Student’s <italic>t</italic>-test, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>H</bold>) Relative gene expression analysis of <italic>Myh1, Myh2, Myh4</italic>, and <italic>Myh7</italic> in quadriceps muscle from WT fed (n = 6) or <italic>Ism1</italic>-KO fed (n = 5) vs. WT fasted (n = 5) or <italic>Ism1</italic>-KO fasted (n = 5) mice (two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Bar graphs show mean ± SEM. See also <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data related to <xref ref-type="fig" rid="fig5">Figure 5A–D,F–H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig5-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Uncropped Western blot images with relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80014-fig5-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig5-v2.tif"/></fig></sec><sec id="s2-6"><title><italic>Ism1</italic>-KO mice have defective skeletal muscle Akt and mTOR signaling and protein synthesis</title><p>To understand the underlying mechanism by which <italic>Ism1</italic>-KO mice develop smaller muscle fiber size, we next asked whether Ism1 directly controls protein content in mice. Quadriceps muscles from 8-week-old mice were harvested and analyzed for total protein content, demonstrating a significant reduction in total protein content in the <italic>Ism1</italic>-KO mice compared with WT mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Because muscle proteostasis is balanced by protein synthesis and degradation (<xref ref-type="bibr" rid="bib16">Glass, 2011</xref>; <xref ref-type="bibr" rid="bib24">Jackman and Kandarian, 2004</xref>), we next tested the hypothesis that Ism1 is required for efficient protein synthesis in mice by measuring in vivo [<sup>35</sup>S]-methionine incorporation into proteins isolated from quadriceps muscles (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). WT and <italic>Ism1</italic>-KO mice were i.p. administered with [<sup>35</sup>S]-methionine for 2 hr, followed by protein precipitation, which demonstrates that loss of Ism1 results in a significant reduction in muscle protein synthesis in mice (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Furthermore, under either fed or fasted conditions, muscles isolated from <italic>Ism1</italic>-KO mice have significantly increased transcript levels of atrophy genes FoxO1 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>), the FoxO target genes <italic>Cdkn1b</italic>, <italic>Eif4ebp1</italic>, and <italic>Ctsl</italic> (<xref ref-type="fig" rid="fig6">Figure 6E</xref>), and ubiquitin ligase <italic>Fbxo30</italic> compared with WT mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), and increased protein levels of the FoxO target p27 (<italic>Cdkn1b</italic>) (<xref ref-type="bibr" rid="bib75">Zhang et al., 2011</xref>; <xref ref-type="fig" rid="fig6">Figure 6F</xref>). These data suggest that Ism1 controls protein synthesis, and its loss is associated with elevated protein degradation gene expression. Given that Ism1 activates the Akt pathway in myocytes in vitro, and that loss of muscle-specific Akt1 and Akt2 leads to muscle atrophy (<xref ref-type="bibr" rid="bib25">Jaiswal et al., 2019</xref>), we next hypothesized that the mechanism behind the smaller muscle fiber size in the <italic>Ism1</italic>-KO mice is due to reduced Akt pathway activity. Indeed, we found that phosphorylation of Akt<sup>S473</sup>, mTOR<sup>2448</sup>, and ribosomal S6<sup>S235/S236</sup> are markedly decreased in <italic>Ism1</italic>-KO muscle compared with WT mice under both fed and fast conditions, providing an explanation for the lower protein synthesis rate (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). <italic>Ism1</italic>-KO mice are indistinguishable from WT mice in the phosphorylation of IRS1 at S307 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), a canonical IRS phosphorylation site (<xref ref-type="bibr" rid="bib57">Rui et al., 2001</xref>). Taken together, these results demonstrate that Ism1 is an anabolic regulator of protein synthesis and muscle strength by maintaining high Akt activity and protein synthesis in skeletal muscle.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>Ism1</italic>-KO mice have defective skeletal muscle protein synthesis and AKT-mTOR signaling.</title><p>(<bold>A</bold>) Total protein content measured in WT and <italic>Ism1</italic>-KO quadriceps muscle expressed as mg protein/wet tissue weight in grams. (WT, n = 12; <italic>Ism1</italic>-KO, n = 9, two-tailed Student’s <italic>t</italic>-test, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>B</bold>) Schematic description of the in vivo [<sup>35</sup>S]-methionine incorporation protocol. (<bold>C</bold>) In vivo protein synthesis measured by [<sup>35</sup>S]-methionine incorporation in WT and <italic>Ism1</italic>-KO mice (WT, n = 12; <italic>Ism1</italic>-KO, n = 9, two-tailed Student’s <italic>t</italic>-test, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Relative gene expression analysis of (<bold>D</bold>) <italic>FoxO</italic> and (<bold>E</bold>) <italic>FoxO</italic> target genes <italic>Cdkn1b, Eif4ebp1,</italic> and <italic>Ctsl</italic> in quadriceps muscle from WT fed (n = 6) or <italic>Ism1</italic>-KO fed (n = 5) vs. WT fasted (n = 5) or <italic>Ism1</italic>-KO fasted (n = 5) mice (two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>F</bold>) Western blot analysis and quantification of the levels of p27 and tubulin in the cytosolic fraction of quadriceps muscles of WT and <italic>Ism1</italic>-KO mice under fed and fasted conditions (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3, WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). (<bold>G</bold>) Western blot analysis and quantification of the levels of pAKT<sup>S473</sup>, total AKT, p-mTOR<sup>S2448</sup>, total mTOR, pS6<sup>S235/236</sup>, total S6, and β-actin in quadriceps muscles of WT and <italic>Ism1</italic>-KO mice under fed and fasted conditions (WT fed, n = 3; <italic>Ism1</italic>-KO fed, n = 3, WT fasted, n = 3; <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Bar graphs show mean ± SEM. See also <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, and <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data related to <xref ref-type="fig" rid="fig6">Figure 6A,C–G</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-80014-fig6-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Uncropped Western blot images with relevant bands labeled.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-80014-fig6-data2-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Ubiquitin expression and insulin receptor substrate-1 (Irs1/2) phosphorylation status in quadriceps muscles of WT and Ism1-KO mice.</title><p>(<bold>A</bold>) Relative gene expression analysis of <italic>Ubiquitin</italic> and the ubiquitin ligase <italic>Fbxo30</italic> in quadriceps muscle from WT fed (n = 6) or <italic>Ism1</italic>-KO fed (n = 5) vs. WT fasted (n = 5) or <italic>Ism1</italic>-KO fasted (n = 5) mice. p-Values are calculated by two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. (<bold>B</bold>) Western blot analysis and quantification of the in vivo levels of p-IRS1 S307, IRS1, and β-actin in quadriceps muscles of WT and <italic>Ism1</italic>-KO mice under fed and fasted conditions (WT fed, n = 3, <italic>Ism1</italic>-KO fed, n = 3, WT fasted, n = 3, <italic>Ism1</italic>-KO fasted, n = 3, two-way ANOVA, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). Bar graphs show mean ± SEM.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-fig6-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Akt has an established role in enhancing muscle hypertrophy and function (<xref ref-type="bibr" rid="bib5">Bodine et al., 2001</xref>; <xref ref-type="bibr" rid="bib16">Glass, 2011</xref>; <xref ref-type="bibr" rid="bib26">Jaiswal et al., 2022</xref>; <xref ref-type="bibr" rid="bib25">Jaiswal et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Lai et al., 2004</xref>; <xref ref-type="bibr" rid="bib39">Mammucari et al., 2007</xref>; <xref ref-type="bibr" rid="bib70">Wilson and Rotwein, 2007</xref>). However, there is still a need to identify other hormonal and physiological insulin/IGF-1 independent activators of Akt to avoid associated side effects such as hypoglycemia when used therapeutically. We previously identified Ism1 as a secreted protein that activates Akt in multiple cell types, including human skeletal muscle cells. Using radiolabeled glucose, we also showed that Ism1 increases glucose transport into both adipose tissue and skeletal muscle (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). Several lines of evidence from this study suggest that Ism1 also has an important anabolic role in promoting skeletal muscle growth. Most importantly, Ism1 acts directly on muscle cells to induce protein synthesis. Conversely, <italic>Ism1</italic> ablation leads to lower skeletal muscle fiber size and atrophy associated with lower Akt signaling and protein synthesis. <italic>Ism1</italic>-KO mice have elevated levels of FoxO1 target genes consistent with increased protein degradation. Therefore, Ism1 appears to be an important protein regulating metabolism during fed and fasted conditions.</p><p>Ism1-induced signaling is not simply an activation of the identical insulin/IGF-1-induced PI3K- Akt pathway. Across multiple cell types, Ism1 and insulin share the pAkt and pS6 network but are seemingly segregated by the more robust activation of pAkt<sup>S473</sup> seen with insulin, whereas Ism1 induces only a subset of shared Akt-induced insulin targets. Interestingly, while Ism1 does not directly phosphorylate the IR/IGFRs, Ism1 does induce phosphorylation of the IR substrate proteins (Irs), a feature that is shared with other endocrine hormones. This phosphospecific regulation by distinct hormones can result in a diverse range of functional outcomes (<xref ref-type="bibr" rid="bib73">Yenush and White, 1997</xref>). For example, Irs1 phosphorylation at S302, S307, S522, and S636/639 have been linked to insulin resistance (<xref ref-type="bibr" rid="bib66">Um et al., 2004</xref>), but not all hormones that phosphorylate those Irs sites induce insulin resistance, including FGF21 (<xref ref-type="bibr" rid="bib42">Minard et al., 2016</xref>). These overlapping but distinct pathways may account for the Ism1’s cell type-specific functional outcomes and downstream transcriptional effects unique to Ism1. Additionally, the phosphoproteomic mapping shows a distinct muscle signature specifically induced by Ism1 and not by insulin. Among Ism1 downstream targets, we find phosphorylation of proteins related to the mTOR pathway, ribosomal and muscle function, targets not previously identified downstream of Ism1.</p><p>In this work, we observe a 60% decrease in pAkt<sup>S473</sup> levels in the muscles of <italic>Ism1</italic>-KO mice, which leads to an ~10% reduction in muscle protein content. Our data is consistent with previous reports using muscle-specific <italic>Akt</italic>-KO mice that demonstrate a 40% reduction in protein synthesis upon complete ablation of Akt (<xref ref-type="bibr" rid="bib26">Jaiswal et al., 2022</xref>). Furthermore, reduced Akt is associated with skeletal muscle insulin resistance, in line with our previous observation that <italic>Ism1</italic>-KO mice fed a high-fat diet are more insulin resistant (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). To what extent the insulin resistance in the <italic>Ism1</italic>-KO mice contributes to muscle function in obesity or during aging is an intriguing question that remains to be answered in future work. Moreover, increasing protein synthesis while suppressing protein degradation is important in a physiological setting, based on the findings that only a combination of FoxO1 inhibition and mTORC1 activation can restore Akt-mediated muscle loss (<xref ref-type="bibr" rid="bib26">Jaiswal et al., 2022</xref>). This suggests that hormonal regulators of Akt activity could have important biological functions because of Akt’s dual role in regulating mTORC1 and the FoxO genes. Here, we used genetic and pharmacological approaches to determine the role of Ism1 in regulating protein synthesis, but it remains to be explored whether pharmacological Ism1 administration prevents protein degradation in the skeletal muscle. Additionally, upon muscle hypertrophy, activated muscle precursors or satellite cells provide an additional mechanism for muscle expansion (<xref ref-type="bibr" rid="bib18">Hawke and Garry, 2001</xref>). A limitation of this study is that we did not investigate whether Ism1 affects muscle regeneration. As IGF-1 induces the growth and differentiation of satellite cells (<xref ref-type="bibr" rid="bib44">Musarò et al., 1999</xref>), and HGF induces activation of cell cycle G<sub>Alert</sub> (<xref ref-type="bibr" rid="bib55">Rodgers et al., 2017</xref>), it will be interesting to determine whether Ism1 also activates skeletal muscle stem cells. Identifying all physiological mechanisms that distinguish Ism1 from IGF-1 will aid in understanding whether other yet unidentified pathways distinct from Akt and FoxO regulate proteostasis.</p><p>The physiological function of Ism1 in regulating muscle growth is expected given that Ism1 stimulates Akt, but it was somewhat unexpected that the lower muscle protein content and fiber size did not lead to a significant loss of muscle mass. Femur length is a basic biometric parameter used to assess longitudinal growth. Femur length and total body weights did not differ between WT and <italic>Ism1</italic>-KO mice, suggesting that the decrease in muscle fiber size is likely not due to growth reduction. It remains to be determined what replaces protein mass in the muscle of <italic>Ism1</italic>-KO mice, including water, glycogen stores, or lipids, which could be regulated by Ism1. Further studies using larger sample sizes are needed to determine whether the effects of Ism1 on muscle proteostasis are specific to fiber types and locations. Notably, <italic>Ism1</italic> itself is not expressed in muscle cells but only in other cells, including adipocytes and immune cells. Circulating levels of human Ism1 using immunoreactive ELISAs have been reported to be in the range of 1–50 ng/ml (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>; <xref ref-type="bibr" rid="bib58">Ruiz-Ojeda et al., 2022</xref>), consistent with mass spectrometry peptide analysis that estimates a circulating Ism1 concentration of 17 ng/ml (<xref ref-type="bibr" rid="bib65">Uhlén et al., 2019</xref>). The necessary circulating and local Ism1 levels to maintain muscle fiber size or prevent fasting-induced muscle loss remain to be determined. It is plausible that Ism1 levels are altered in response to fasting and feeding, insulin resistance, or aging – conditions associated with temporary or chronic muscle loss (<xref ref-type="bibr" rid="bib32">Laurens et al., 2021</xref>; <xref ref-type="bibr" rid="bib51">Perry et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Roubenoff and Castaneda, 2001</xref>). As this study was conducted in male mice only, it is unknown whether Ism1 deficiency results in any muscle phenotype in female mice. Further studies are required to test whether Ism1 regulates muscle proteostasis in a sex-specific manner. A limitation of this study is that fasting but not more severe atrophy conditions were studied. Long-term studies ought to explore whether pharmacological administration of Ism1 systemically or locally into the muscle is sufficient to induce muscle hypertrophy or prevent muscle loss in more severe models of muscle loss. Nevertheless, as aging impairs skeletal muscle protein synthesis and leads to muscle weakness and atrophy, this work has implications for multiple conditions, including diabetes- and age-induced muscle atrophy.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Animal studies</title><p>Animal experiments were performed per procedures approved by the Institutional Animal Care and Use Committee of the Stanford Animal Care and Use Committee (APLAC) protocol number #32982. C57BL/6J mice were purchased from the Jackson Laboratory (#000664). The <italic>Ism1</italic>-KO mice (C57BL/6J-Ism1<sup>em1Kajs</sup>/J strain #036776, JAX) were generated using the <italic>Ism1</italic> floxed allele as described previously (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). Unless otherwise stated, mice were maintained on a chow diet (Envigo Teklad Global 18% Protein Rodent Diet 2018) and housed in a temperature-controlled (20–22°C) room on a 12 hr light/dark cycle. All experiments were performed with age-matched male mice housed in groups of five unless stated otherwise.</p></sec><sec id="s4-2"><title>Sample preparation for phosphoproteomics analysis</title><p>The phosphoproteomics analysis was performed using 3T3-F442A cells. The 3T3-F442A cell line is mycoplasma negative and has been authenticated with STR. Cells were cultured in DMEM/F12 medium with 10% FBS/1% pen/strep until 80–100% confluent. Following a 16 hr starvation in serum-free DMEM/F12 medium, cells were treated with PBS, 100 nM Ism1 or 100 nM insulin for 5 min (N = 6 per treatment group, 10M cells/treatment). Following treatment, the medium was aspirated, and cells were washed three times with ice-cold PBS while kept on ice. Then, 1 ml ice-cold PBS supplemented with cOmplete Mini Protease Inhibitors (#4693124001, Sigma-Aldrich, St. Louis, MO) and phosSTOP phosphatase inhibitors (#4906845001, Sigma-Aldrich) were added to the cells that were immediately scraped down, pelleted at 14,000 ×<italic> g</italic> for 10 min followed by snap freezing. Cell pellets were kept at –80°C until analysis. Aliquots of the samples were used to verify AKT<sup>S473</sup> signaling induction by Ism1 and insulin by Western blot. For each treatment group, six biological replicates were pooled into two technical replicates for the phosphoproteomics analysis. The phosphoproteomics analysis was performed at Northwestern University Proteomics core as described previously (<xref ref-type="bibr" rid="bib12">Dephoure et al., 2013</xref>). Briefly, protein extracts were alkylated with iodoacetamide and digested with trypsin at a ratio of 1:50 (w/w) trypsin to protein. Tryptic phosphopeptides were enriched by TiO<sub>2</sub>-immobilized metal affinity chromatography, washed with 70% (v/v) EtOH, and equilibrated in 1% NH<sub>4</sub>OH and three times in 1 M glycolic acid in 80% (v/v) acetonitrile, 5% (v/v) trifluoroacetic acid. Peptides were eluted and dried in a SpeedVac concentrator. Peptides were resuspended in 3% (v/v) acetonitrile, 0.1% trifluoroacetic acid, and twice in 0.1% trifluoroacetic acid. Dried peptides were dissolved in LC-MS/MS solvent (3% acetonitrile and 0.1% fluoroacetic acid) prior to LC-MS/MS analysis using a dual-pressure linear ion trap (Velos Pro) with a high-field Orbitrap mass analyzer as described previously (<xref ref-type="bibr" rid="bib74">Yue et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Zhou et al., 2008</xref>) using MaxQuant to analyze raw spectrometry data (<xref ref-type="bibr" rid="bib64">Tyanova et al., 2016</xref>).</p></sec><sec id="s4-3"><title>Phosphoproteomic analysis</title><p>Data acquired on the Orbitrap were searched against a UniProt <italic>Mus musculus</italic> protein database using TDPortal as previously described (<xref ref-type="bibr" rid="bib15">Fornelli et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Tyanova et al., 2016</xref>). Annotations were extracted from UniProtKB, Gene Ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Bioinformatics analyses including hierarchical clustering, pathway analysis, and annotation enrichment were performed with R v4.1.1 using the DEP package (<xref ref-type="bibr" rid="bib76">Zhang et al., 2018</xref>) employing filtering of phosphopeptides identified in less than one-third of samples, variance stabilization for normalization, and maximal reduction of variation between replicates (<xref ref-type="bibr" rid="bib21">Huber et al., 2002</xref>) and imputation. Tests for significance were based on limma, which have a higher sensitivity compared to other algorithms (<xref ref-type="bibr" rid="bib68">van Ooijen et al., 2018</xref>). To achieve a normal distribution, we log2 transformed data after normalization. Missing data, which due to matrix effects are common to proteomics data, were not missing at random; we therefore tested conclusions using the MinProb, man, and QRILC imputation methods appropriate for left censored data (<xref ref-type="bibr" rid="bib33">Lazar et al., 2016</xref>). For all analyses, we used the MinProb algorithm as it yielded the lowest number of significant phosphopeptides while retaining large overlap with the two other methods. Since imputation is non-deterministic, in a minority of cases the IR would not be significantly phosphorylated by insulin. To minimize random effects of imputation, we performed 200 permutations of imputations and testing for significance followed by calculation of the median p-value. Using this algorithm, the IR was consistently found to be phosphorylated by insulin versus BSA, and running the algorithm repeatedly only results in changes to conclusions for 2–3 phosphosites. Pathway enrichment was analyzed using the TopGO package using the classic Kolmogorov–Smirnov test (<xref ref-type="bibr" rid="bib1">Alexa and Rahnenfuhrer, 2010</xref>, topGO: Enrichment Analysis for Gene Ontology. R package version 2.48.0). To calculate the significance between proteomic samples with a sample size of 2, we used the DEP package. The DEP package employs limma for statistical testing. This package uses the <italic>t</italic>-test except that the standard errors have been moderated across genes, that is, shrunk toward a common value, using a simple Bayesian model (<xref ref-type="bibr" rid="bib68">van Ooijen et al., 2018</xref>). The assumptions for limma are that the data are normally distributed and equal variance between replicates. These assumptions were met after normalization and log2 transformation. For the proteomics analysis, we calculated the significance based on imputed values. Zeros were more abundant for phosphopeptides with an overall low intensity across the samples. Therefore, the choice of imputation method was based on data missing not at random (MNAR). We tested three imputation methods and continued with the one resulting in the lowest number of significant phosphopeptides retaining a relatively large overlap with other imputation methods. In cases where phosphorylation was displayed as zero, the intensity was zero in the raw dataset. We applied semantic similarity analysis between GO terms followed by principal coordinates analysis to cluster and visualize enrichments. Unless otherwise stated, individual comparisons between conditions across phosphopeptides were performed using empirical Bayes statistics followed by adjustment for multiple testing with p-values of *&lt;0.05, **&lt;0.01, and ***&lt;0.001 to be considered significant. The minimum normalized intensity across the dataset was subtracted from each normalized data point, and phosphorylation was calculated as a fraction of the maximum value of all samples for each phosphopeptide. Plotted GO terms have p-values &lt;0.01 calculated using the classic Kolmogorov–Smirnov test. The distribution diagram of shared and unique phosphosites was obtained by retrieving the selected GO pathways for peptides detected in at least one sample between treatments. Specific details on the significance of each test are described in the figure legends. The raw data for this analysis is presented in <xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>.</p></sec><sec id="s4-4"><title>Immunohistochemistry and muscle fiber size quantification</title><p>Tissues were snap-frozen in liquid nitrogen-cooled isopentane and cross-sectioned at 10 μm (<xref ref-type="bibr" rid="bib7">Brett et al., 2020</xref>). Sections from muscles were fixed using 4% PFA, permeabilized using 0.2% Triton X-100 in PBS, blocked using 1% BSA in PBS, and incubated with anti-laminin antibody (Millipore, clone A5, Cat# 05-206, 1:200) and then with Alexa Fluor secondary antibodies (#A11007, Invitrogen, 1:1000). Nuclei were counterstained with Hoechst (#33342, Thermo Fisher, 1:1000). Images were acquired using a confocal microscope (Leica TCS SP8) at 63×. For hematoxylin and eosin (H&amp;E) staining, slides were stained with hematoxylin for 3 min, washed with water and 95% ethanol, and stained with eosin for 30 min. Sections were then washed with ethanol and xylene, and mounted with mounting medium. The tissue slides were observed with a Nikon 80i upright light microscope using a ×20 objective lens. Digital images were captured with a Nikon Digital Sight DS-Fi1 color camera and NIS-Elements acquisition software. Muscle fiber sizes for the pectoralis, quadriceps, soleus, gastrocnemius, and tibialis muscle tissues were determined by measuring cross-sectional area (μm<sup>2</sup>) using the Image J (version 1.53e) software. The muscle fibers were manually outlined to obtain their measurement data. Blind scoring by two independent investigators of the muscle tissues was done to unbiasedly collect data for all categories of mice. The quantification of the average muscle fiber area was performed using n = 3 independent muscle tissues from each genotype, with 2–4 photos taken from each muscle tissue. Approximately 60–100 myofibers were quantified per image, and average area values were calculated for each image. Statistically significant differences were determined using two-way ANOVA.</p></sec><sec id="s4-5"><title>Indirect calorimetry, food intake, and physiological measurements</title><p>Oxygen consumption (VO<sub>2</sub>), RER, movement, and food intake in 8-to-12-week-old WT and <italic>Ism1</italic>-KO mice were measured using the environment-controlled home-cage CLAMS system (Columbus Instruments, Columbus, OH) at the Stanford Diabetes Research Center. Mice were maintained on a chow diet (Envigo Teklad Global 18% Protein Rodent Diet 2018) and housed at 20–22°C in the cages for 24 hr prior to the recording. Energy expenditure calculations were not normalized for body weight. RER and locomotion were analyzed using ANOVA. All other calorimetry measurements in mice were analyzed using ANCOVA using the CalR version 1.3 without the remove outliers feature (<xref ref-type="bibr" rid="bib41">Mina et al., 2018</xref>). The two-paw grip strength was measured on a grid with a grip meter. The mice were trained to grasp a horizontal bar while being pulled by their tail. The force (expressed in Newton) was recorded by a sensor. Three trials were combined for analysis.</p></sec><sec id="s4-6"><title>Femur length measurement</title><p>Both left and right femurs from each mouse were carefully dissected, and the length between the distal and proximal ends of the bone was measured with a ruler. The average value of the left and right femurs of each individual mouse was used for data analysis. Statistical significance was calculated using a two-tailed Student’s <italic>t</italic>-test.</p></sec><sec id="s4-7"><title>Single-cell RNA sequencing of skeletal muscle in mice</title><p>Single-cell RNA sequencing data was reanalyzed from a previously published dataset performed on single-cell suspension from murine tibialis anterior skeletal muscles (<xref ref-type="bibr" rid="bib3">Baht et al., 2020</xref>). Briefly, tibialis anterior muscles from three injured mice were pooled as well as three uninjured mice to generate two samples used for scRNA-Seq. Three thousand single cells from each of the two samples were barcoded and cDNA generated using 10X Genomics Chromium Drop-seq platform and sequencing on Illumina 2500 platform. 10X Genomics Cell Ranger software was used to demultiplex and align reads. Seurat (V4.2) package was used to perform quality control, sample normalization, and clustering for cell type identification. Downstream analyses included gene analysis of the genes of interests associated with cell clusters.</p></sec><sec id="s4-8"><title>Expression and purification of recombinant proteins</title><p>The Ism1 proteins were generated by transient transfection of mouse Ism1 with C-terminal Myc-6X-his tag DNA plasmids Addgene (#173046) into Expi293F cells. The Expi293F cell line is mycoplasma negative and has been authenticated with STR. Recombinant proteins were produced in mammalian Expi293F cells using large-scale transient DNA transfection and purified using Cobalt columns and buffer exchanged to PBS. Protein purity and integrity were assessed with SDS-PAGE, Superdex200 size-exclusion column and endotoxin assay. Every protein batch produced was tested for bioactivity by measuring the induction of pAKT<sup>S473</sup> signaling in 3T3-F442A cells as described previously (<xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref>). All proteins were aliquoted and stored at –80°C and not used for more than three freeze-thaws.</p></sec><sec id="s4-9"><title>Culture and differentiation of C2C12 cells</title><p>C2C12 cells (#CRL-1772, ATCC) were cultured in DMEM with 10% FBS. The C2C12 cell line is mycoplasma negative and has been authenticated with STR. Cells were passaged every 2 days and were not allowed to reach more than 70% confluency. C2C12 cells were used in the state of myotubes or myoblasts as indicated in figure legends. To differentiate C2C12 cells from myoblasts to myotubes, cells were cultured in differentiation medium (<xref ref-type="bibr" rid="bib54">Risson et al., 2009</xref>; <xref ref-type="bibr" rid="bib59">Sandri et al., 2004</xref>). Cells with passage numbers 6–11 were used for all experiments.</p></sec><sec id="s4-10"><title>In vivo and in vitro protein synthesis</title><p>In vivo protein synthesis was measured by incorporation of [<sup>35</sup>S]-methionine into proteins isolated from skeletal muscle in mice. Briefly, mice fasted for 1 hr were i.p. injected with 2.5 μCi/g [<sup>35</sup>S]-methionine diluted in saline. Then, 2 hr after injection, the quadriceps muscles were removed, weighed, and snap-frozen in liquid nitrogen. The tissues were homogenized using a hand-held homogenizer in RIPA buffer containing protease inhibitor cocktail (Roche) and centrifuged at 4°C to remove cell debris. Protein concentration in the supernatant was determined by BCA assay (Thermo Fisher Scientific, Waltham, MA), and total protein content was calculated by multiplying the protein concentration by the supernatant volume. Proteins were extracted using TCA precipitation and the radioactivity was counted on a scintillation counter. Protein synthesis in C2C12 myotubes was measured by incorporation of [<sup>35</sup>S]-methionine into proteins using a modified protocol developed for skeletal myotubes (<xref ref-type="bibr" rid="bib20">Hong-Brown et al., 2007</xref>; <xref ref-type="bibr" rid="bib29">Kazi and Lang, 2010</xref>; <xref ref-type="bibr" rid="bib40">Méchin et al., 2007</xref>) as described previously (<xref ref-type="bibr" rid="bib61">Schmidt et al., 2009</xref>). For [<sup>35</sup>S]-methionine incorporation, C2C12 cells were treated with BSA, recombinant Ism1 or Igf1 with the addition of 0.5 μCi [<sup>35</sup>S]-methionine (#NEG009L005MC, PerkinElmer, Waltham, MA) for 48 hr. For [<sup>35</sup>S]-methionine incorporation in the presence or absence of inhibitors, C2C12 cells were treated with DMSO or 100 nM rapamycin for 2 hr, followed by treatments with BSA, recombinant Ism1 or Igf1 for 1 hr. Subsequently, 0.5 μCi [<sup>35</sup>S]-methionine (#NEG009L005MC, PerkinElmer) was added for another 1 hr. To stop the incubation, cells were washed in ice-cold PBS three times. Proteins were extracted using TCA precipitation, and the radioactivity was counted on a scintillation counter.</p></sec><sec id="s4-11"><title>Gene expression analysis</title><p>Total RNA from cultured cells or tissues was isolated using TRIzol (Thermo Fisher Scientific) and RNeasy mini kits (QIAGEN, Hilden, Germany). RNA was reverse transcribed using the ABI high-capacity cDNA synthesis kit. For q-RT-pcr analysis, cDNA, primers, and SYBR-green fluorescent dye (Bimake, Houston, TX) were used. Relative mRNA expression was determined by normalization to cyclophilin levels using the ΔΔCt method.</p></sec><sec id="s4-12"><title>Western blots and molecular analyses</title><p>For Western blotting, homogenized tissues or whole-cell lysates were lysed in RIPA buffer containing protease inhibitor cocktail (Roche, Basel, Switzerland) and phosphatase inhibitor cocktail (Roche), prepared in 4X LDS Sample Buffer (Invitrogen, Waltham, MA) and separated by SDS-PAGE and transferred to Immobilon 0.45 µm membranes (Millipore, Burlington, MA). The cytoplasmic fraction was isolated using a Nuclear Cytoplasmic Extraction Reagent kit (78833, Pierce, Rockford, IL) according to the manufacturer’s instructions. The antibodies used are as follows: rabbit monoclonal anti-p-AKT1/2 (Ser473) (#4060), AKT1 (pan) (#4691 CST), rabbit monoclonal anti-p-mTOR (Ser2448) (D9C2), rabbit polyclonal anti-p-S6 ribosomal protein (Ser235/236) (Cat# 2211 CST), and ribosomal protein S6 (#2217 CST) from Cell Signaling. Mouse monoclonal anti-beta actin AC-15 HRP (#AB49900) and OXPHOS rodent antibody (#ab110413) were from Abcam. Donkey anti-rabbit IgG (HRP) (#NA934) and sheep anti-mouse IgG (HRP) (#NA931) were from Cytiva (GE). Recombinant Igf1 (#791-MG-050) was from R&amp;D Systems. The mammalian expression plasmid for Ism1 with C-terminal myc-6xhis tag plasmid for recombinant Ism1 protein production was from Addgene (#173046). The raw Western blot images are presented in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p></sec><sec id="s4-13"><title>Statistical analyses</title><p>Values for <italic>N</italic> represent biological replicates for cultured cell experiments or individual animals for in vivo experiments. Group-housed mice within 8 weeks of age were used for comparative studies. Mice were randomly assigned to treatment groups for in vivo studies. Significant differences between the two groups (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001) were evaluated using a two-tailed, unpaired Student’s <italic>t</italic>-test as the sample groups displayed a normal distribution and comparable variance (Prism9 software; GraphPad). Two-way ANOVA with repeated measures was used for body weight and repeated measurements (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001). All data are presented as the standard error of mean (SEM) or as described in the figure legends. Specific details for <italic>N</italic> values are noted in each figure legend.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Visualization</p></fn><fn fn-type="con" id="con7"><p>Data curation, Visualization</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation</p></fn><fn fn-type="con" id="con10"><p>Data curation</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con12"><p>Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experiments were performed per procedures approved by the Institutional Animal Care and Use Committee of the Stanford Animal Care and Use Committee (APLAC) protocol number #32982.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-80014-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Unedited raw Western blot images in <xref ref-type="fig" rid="fig1">Figures 1</xref>, <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig5">5</xref> and <xref ref-type="fig" rid="fig6">6</xref>.</title></caption><media xlink:href="elife-80014-data1-v2.zip" mimetype="application" mime-subtype="zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Source data for the phosphoproteomic analysis and quality control.</title></caption><media xlink:href="elife-80014-data2-v2.zip" mimetype="application" mime-subtype="zip"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The phosphoproteomics dataset has been deposited to ProteomeXchange Consortium through JPost PXD031719 (JPST001484) (<xref ref-type="bibr" rid="bib45">Okuda et al., 2017</xref>). The code for all analysis related to phosphoproteomic data is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/Svensson-Lab/Isthmin-1">https://github.com/Svensson-Lab/Isthmin-1</ext-link> (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:82d8a0395b2ff75871561dfc6ecc7ac516afc7d4;origin=https://github.com/Svensson-Lab/Isthmin-1;visit=swh:1:snp:204f8061af2a7ebd13e3085e3f9dd8b02efc86f4;anchor=swh:1:rev:8d60d65fb98a00d6dfdc8b5fadefe17ce11d25af">swh:1:rev:8d60d65fb98a00d6dfdc8b5fadefe17ce11d25af</ext-link>). The single-cell RNA sequencing data was re-analyzed from a previously published dataset (<xref ref-type="bibr" rid="bib3">Baht et al., 2020</xref>). All the other data generated or analyzed in this study are included in the manuscript and supporting files.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Phosphoproteomic dataset of Ism1 recombinant protein treatment</data-title><source>ProteomeXchange</source><pub-id pub-id-type="accession" xlink:href="http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD031719">PXD031719</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Baht</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single Cell RNAseq on whole muscle one day after injury and uninjured control</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145236">GSE145236</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>KJS was supported by NIH grants DK125260, DK111916, the Stanford Diabetes Research Center P30 DK116074, the Jacob Churg Foundation, the McCormick and Gabilan Award, the Weintz Family COVID-19 research fund, American Heart Association (AHA), the Stanford School of Medicine, and the Stanford Cardiovascular Institute (CVI). MZ was supported by the American Heart Association (AHA) postdoctoral fellowship (905674). LV was supported by Stanford School of Medicine Dean’s Postdoctoral Fellowship. EBM was supported by Stanford School of Medicine Dean’s Postdoctoral Fellowship and the American Heart Association (AHA) postdoctoral fellowship (18POST34030448). DEL was supported by NIH training grant T32HL007057. JPW was supported by NIH/NIA grants K01AG056664 and R21AG065943 and Borden Scholar Award through Duke University. NC was supported by the American Heart Association (AHA) SURE award (882082). NBDS was supported by the Carlsberg Foundation Internationalization Fellowship. CVR was supported by the Weintz family COVID-19 research fund, the Stanford Women’s Cancer Center and the Stanford Cancer Institute, The Jacob Churg award, and the Children’s Cancer Research Foundation. We thank the Stanford University Pathology Histology core facility and the Pathology Department for microscopy equipment. We thank the Proteomics core at Northwestern University for assistance with the phosphoproteomic analysis and Pratima Nallagatla at Stanford University for assistance with the data processing. This work was supported by the Stanford Diabetes Research Center (NIH grant P30DK116074). Some illustrations were created with Biorender under a paid subscription.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Alexa</surname><given-names>A</given-names></name><name><surname>Rahnenfuhrer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><data-title>TopGO: enrichment analysis for gene ontology</data-title><source>R Package Version 2</source></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>S</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Jakobsen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Muscle strength in type 2 diabetes</article-title><source>Diabetes</source><volume>53</volume><fpage>1543</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.2337/diabetes.53.6.1543</pub-id><pub-id pub-id-type="pmid">15161759</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baht</surname><given-names>GS</given-names></name><name><surname>Bareja</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>DE</given-names></name><name><surname>Rao</surname><given-names>RR</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Huebner</surname><given-names>JL</given-names></name><name><surname>Bartlett</surname><given-names>DB</given-names></name><name><surname>Hart</surname><given-names>CR</given-names></name><name><surname>Gibson</surname><given-names>JR</given-names></name><name><surname>Lanza</surname><given-names>IR</given-names></name><name><surname>Kraus</surname><given-names>VB</given-names></name><name><surname>Gregory</surname><given-names>SG</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>White</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Meteorin-like facilitates skeletal muscle repair through a stat3/IGF-1 mechanism</article-title><source>Nature Metabolism</source><volume>2</volume><fpage>278</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-0184-y</pub-id><pub-id pub-id-type="pmid">32694780</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>G</given-names></name><name><surname>Penniman</surname><given-names>CM</given-names></name><name><surname>Jena</surname><given-names>J</given-names></name><name><surname>Suarez Beltran</surname><given-names>PA</given-names></name><name><surname>Foster</surname><given-names>C</given-names></name><name><surname>Poro</surname><given-names>K</given-names></name><name><surname>Junck</surname><given-names>TL</given-names></name><name><surname>Hinton</surname><given-names>AO</given-names></name><name><surname>Souvenir</surname><given-names>R</given-names></name><name><surname>Fuqua</surname><given-names>JD</given-names></name><name><surname>Morales</surname><given-names>PE</given-names></name><name><surname>Bravo-Sagua</surname><given-names>R</given-names></name><name><surname>Sivitz</surname><given-names>WI</given-names></name><name><surname>Lira</surname><given-names>VA</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name><name><surname>O’Neill</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Insulin and IGF-1 receptors regulate complex I-dependent mitochondrial bioenergetics and supercomplexes via FoxOs in muscle</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>146415</elocation-id><pub-id pub-id-type="doi">10.1172/JCI146415</pub-id><pub-id pub-id-type="pmid">34343133</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodine</surname><given-names>SC</given-names></name><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Kline</surname><given-names>WO</given-names></name><name><surname>Stover</surname><given-names>GL</given-names></name><name><surname>Bauerlein</surname><given-names>R</given-names></name><name><surname>Zlotchenko</surname><given-names>E</given-names></name><name><surname>Scrimgeour</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>JC</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Akt/Mtor pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo</article-title><source>Nature Cell Biology</source><volume>3</volume><fpage>1014</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1038/ncb1101-1014</pub-id><pub-id pub-id-type="pmid">11715023</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodine</surname><given-names>SC</given-names></name><name><surname>Baehr</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/Atrogin-1</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>307</volume><fpage>E469</fpage><lpage>E484</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00204.2014</pub-id><pub-id pub-id-type="pmid">25096180</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brett</surname><given-names>JO</given-names></name><name><surname>Arjona</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Quarta</surname><given-names>M</given-names></name><name><surname>de Morrée</surname><given-names>A</given-names></name><name><surname>Egner</surname><given-names>IM</given-names></name><name><surname>Perandini</surname><given-names>LA</given-names></name><name><surname>Ishak</surname><given-names>HD</given-names></name><name><surname>Goshayeshi</surname><given-names>A</given-names></name><name><surname>Benjamin</surname><given-names>DI</given-names></name><name><surname>Both</surname><given-names>P</given-names></name><name><surname>Rodríguez-Mateo</surname><given-names>C</given-names></name><name><surname>Betley</surname><given-names>MJ</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Rando</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Exercise rejuvenates quiescent skeletal muscle stem cells in old mice through restoration of cyclin D1</article-title><source>Nature Metabolism</source><volume>2</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-0190-0</pub-id><pub-id pub-id-type="pmid">32601609</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauvin</surname><given-names>C</given-names></name><name><surname>Koka</surname><given-names>V</given-names></name><name><surname>Nouschi</surname><given-names>A</given-names></name><name><surname>Mieulet</surname><given-names>V</given-names></name><name><surname>Hoareau-Aveilla</surname><given-names>C</given-names></name><name><surname>Dreazen</surname><given-names>A</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Kiss</surname><given-names>T</given-names></name><name><surname>Meyuhas</surname><given-names>O</given-names></name><name><surname>Pende</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program</article-title><source>Oncogene</source><volume>33</volume><fpage>474</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.606</pub-id><pub-id pub-id-type="pmid">23318442</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Friesel</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fgfr1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expression</article-title><source>Biochemical and Biophysical Research Communications</source><volume>382</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.03.040</pub-id><pub-id pub-id-type="pmid">19285959</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>WS</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A cdh1-foxm1-apc axis controls muscle development and regeneration</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-2375-6</pub-id><pub-id pub-id-type="pmid">32152291</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Nathan</surname><given-names>JA</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Muscle wasting in disease: molecular mechanisms and promising therapies</article-title><source>Nature Reviews. Drug Discovery</source><volume>14</volume><fpage>58</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nrd4467</pub-id><pub-id pub-id-type="pmid">25549588</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dephoure</surname><given-names>N</given-names></name><name><surname>Gould</surname><given-names>KL</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Kellogg</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mapping and analysis of phosphorylation sites: a quick guide for cell biologists</article-title><source>Molecular Biology of the Cell</source><volume>24</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1091/mbc.E12-09-0677</pub-id><pub-id pub-id-type="pmid">23447708</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Insulin-Stimulated glucose uptake in healthy and insulin-resistant skeletal muscle</article-title><source>Hormone Molecular Biology and Clinical Investigation</source><volume>26</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1515/hmbci-2015-0041</pub-id><pub-id pub-id-type="pmid">26485752</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edinger</surname><given-names>AL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake</article-title><source>Molecular Biology of the Cell</source><volume>13</volume><fpage>2276</fpage><lpage>2288</lpage><pub-id pub-id-type="doi">10.1091/mbc.01-12-0584</pub-id><pub-id pub-id-type="pmid">12134068</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornelli</surname><given-names>L</given-names></name><name><surname>Durbin</surname><given-names>KR</given-names></name><name><surname>Fellers</surname><given-names>RT</given-names></name><name><surname>Early</surname><given-names>BP</given-names></name><name><surname>Greer</surname><given-names>JB</given-names></name><name><surname>LeDuc</surname><given-names>RD</given-names></name><name><surname>Compton</surname><given-names>PD</given-names></name><name><surname>Kelleher</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Advancing top-down analysis of the human proteome using a benchtop quadrupole-orbitrap mass spectrometer</article-title><source>Journal of Proteome Research</source><volume>16</volume><fpage>609</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.6b00698</pub-id><pub-id pub-id-type="pmid">28152595</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pi3 kinase regulation of skeletal muscle hypertrophy and atrophy</article-title><source>Current Topics in Microbiology and Immunology</source><volume>346</volume><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/82_2010_78</pub-id><pub-id pub-id-type="pmid">20593312</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>MD</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Jagoe</surname><given-names>RT</given-names></name><name><surname>Navon</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy</article-title><source>PNAS</source><volume>98</volume><fpage>14440</fpage><lpage>14445</lpage><pub-id pub-id-type="doi">10.1073/pnas.251541198</pub-id><pub-id pub-id-type="pmid">11717410</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawke</surname><given-names>TJ</given-names></name><name><surname>Garry</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Myogenic satellite cells: physiology to molecular biology</article-title><source>Journal of Applied Physiology</source><volume>91</volume><fpage>534</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1152/jappl.2001.91.2.534</pub-id><pub-id pub-id-type="pmid">11457764</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedberg-Oldfors</surname><given-names>C</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Nolte</surname><given-names>K</given-names></name><name><surname>Abdul Rahim</surname><given-names>Y</given-names></name><name><surname>Lindberg</surname><given-names>C</given-names></name><name><surname>Karason</surname><given-names>K</given-names></name><name><surname>Thuestad</surname><given-names>IJ</given-names></name><name><surname>Visuttijai</surname><given-names>K</given-names></name><name><surname>Geijer</surname><given-names>M</given-names></name><name><surname>Begemann</surname><given-names>M</given-names></name><name><surname>Kraft</surname><given-names>F</given-names></name><name><surname>Lausberg</surname><given-names>E</given-names></name><name><surname>Hitpass</surname><given-names>L</given-names></name><name><surname>Götzl</surname><given-names>R</given-names></name><name><surname>Luna</surname><given-names>EJ</given-names></name><name><surname>Lochmüller</surname><given-names>H</given-names></name><name><surname>Koschmieder</surname><given-names>S</given-names></name><name><surname>Gramlich</surname><given-names>M</given-names></name><name><surname>Gess</surname><given-names>B</given-names></name><name><surname>Elbracht</surname><given-names>M</given-names></name><name><surname>Weis</surname><given-names>J</given-names></name><name><surname>Kurth</surname><given-names>I</given-names></name><name><surname>Oldfors</surname><given-names>A</given-names></name><name><surname>Knopp</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Loss of supervillin causes myopathy with myofibrillar disorganization and autophagic vacuoles</article-title><source>Brain</source><volume>143</volume><fpage>2406</fpage><lpage>2420</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa206</pub-id><pub-id pub-id-type="pmid">32779703</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong-Brown</surname><given-names>LQ</given-names></name><name><surname>Brown</surname><given-names>CR</given-names></name><name><surname>Huber</surname><given-names>DS</given-names></name><name><surname>Lang</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Alcohol regulates eukaryotic elongation factor 2 phosphorylation via an AMP-activated protein kinase-dependent mechanism in C2C12 skeletal myocytes</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>3702</fpage><lpage>3712</lpage><pub-id pub-id-type="doi">10.1074/jbc.M606593200</pub-id><pub-id pub-id-type="pmid">17164244</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>von Heydebreck</surname><given-names>A</given-names></name><name><surname>Sültmann</surname><given-names>H</given-names></name><name><surname>Poustka</surname><given-names>A</given-names></name><name><surname>Vingron</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Variance stabilization applied to microarray data calibration and to the quantification of differential expression</article-title><source>Bioinformatics</source><volume>18 Suppl 1</volume><fpage>S96</fpage><lpage>S104</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/18.suppl_1.s96</pub-id><pub-id pub-id-type="pmid">12169536</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>SJ</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>Stöckli</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>1009</fpage><lpage>1020</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.010</pub-id><pub-id pub-id-type="pmid">23684622</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>SJ</given-names></name><name><surname>James</surname><given-names>DE</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protein phosphorylation: a major switch mechanism for metabolic regulation</article-title><source>Trends in Endocrinology and Metabolism</source><volume>26</volume><fpage>676</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.09.013</pub-id><pub-id pub-id-type="pmid">26498855</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackman</surname><given-names>RW</given-names></name><name><surname>Kandarian</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The molecular basis of skeletal muscle atrophy</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>287</volume><fpage>C834</fpage><lpage>C843</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00579.2003</pub-id><pub-id pub-id-type="pmid">15355854</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>N</given-names></name><name><surname>Gavin</surname><given-names>MG</given-names></name><name><surname>Quinn</surname><given-names>WJ</given-names></name><name><surname>Luongo</surname><given-names>TS</given-names></name><name><surname>Gelfer</surname><given-names>RG</given-names></name><name><surname>Baur</surname><given-names>JA</given-names></name><name><surname>Titchenell</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis</article-title><source>Molecular Metabolism</source><volume>28</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.08.001</pub-id><pub-id pub-id-type="pmid">31444134</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaiswal</surname><given-names>N</given-names></name><name><surname>Gavin</surname><given-names>M</given-names></name><name><surname>Loro</surname><given-names>E</given-names></name><name><surname>Sostre-Colón</surname><given-names>J</given-names></name><name><surname>Roberson</surname><given-names>PA</given-names></name><name><surname>Uehara</surname><given-names>K</given-names></name><name><surname>Rivera-Fuentes</surname><given-names>N</given-names></name><name><surname>Neinast</surname><given-names>M</given-names></name><name><surname>Arany</surname><given-names>Z</given-names></name><name><surname>Kimball</surname><given-names>SR</given-names></name><name><surname>Khurana</surname><given-names>TS</given-names></name><name><surname>Titchenell</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Akt controls protein synthesis and oxidative metabolism via combined mTORC1 and FoxO1 signalling to govern muscle physiology</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><volume>13</volume><fpage>495</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12846</pub-id><pub-id pub-id-type="pmid">34751006</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Heymsfield</surname><given-names>SB</given-names></name><name><surname>Wang</surname><given-names>ZM</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr</article-title><source>Journal of Applied Physiology</source><volume>89</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1152/jappl.2000.89.1.81</pub-id><pub-id pub-id-type="pmid">10904038</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Voilquin</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Aikio</surname><given-names>MA</given-names></name><name><surname>Sahai</surname><given-names>T</given-names></name><name><surname>Dou</surname><given-names>FY</given-names></name><name><surname>Roche</surname><given-names>AM</given-names></name><name><surname>Carcamo-Orive</surname><given-names>I</given-names></name><name><surname>Knowles</surname><given-names>JW</given-names></name><name><surname>Wabitsch</surname><given-names>M</given-names></name><name><surname>Appel</surname><given-names>EA</given-names></name><name><surname>Maikawa</surname><given-names>CL</given-names></name><name><surname>Camporez</surname><given-names>JP</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Tsai</surname><given-names>L</given-names></name><name><surname>Rosen</surname><given-names>ED</given-names></name><name><surname>Gardner</surname><given-names>CD</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Svensson</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>1836</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.07.010</pub-id><pub-id pub-id-type="pmid">34348115</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazi</surname><given-names>AA</given-names></name><name><surname>Lang</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Pras40 regulates protein synthesis and cell cycle in C2C12 myoblasts</article-title><source>Molecular Medicine</source><volume>16</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.2119/molmed.2009.00168</pub-id><pub-id pub-id-type="pmid">20464060</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>KMV</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Poueymirou</surname><given-names>WT</given-names></name><name><surname>Kline</surname><given-names>WO</given-names></name><name><surname>Na</surname><given-names>E</given-names></name><name><surname>Zlotchenko</surname><given-names>E</given-names></name><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Economides</surname><given-names>AN</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Conditional activation of Akt in adult skeletal muscle induces rapid hypertrophy</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>9295</fpage><lpage>9304</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.21.9295-9304.2004</pub-id><pub-id pub-id-type="pmid">15485899</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>TYW</given-names></name><name><surname>Nguyen</surname><given-names>N</given-names></name><name><surname>Peh</surname><given-names>HY</given-names></name><name><surname>Shanmugasundaram</surname><given-names>M</given-names></name><name><surname>Chandna</surname><given-names>R</given-names></name><name><surname>Tee</surname><given-names>JH</given-names></name><name><surname>Ong</surname><given-names>CB</given-names></name><name><surname>Hossain</surname><given-names>MZ</given-names></name><name><surname>Venugopal</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>T</given-names></name><name><surname>Kong</surname><given-names>WT</given-names></name><name><surname>Chakarov</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Teh</surname><given-names>M</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Fred Wong</surname><given-names>WS</given-names></name><name><surname>Ge</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ISM1 protects lung homeostasis via cell-surface GRP78-mediated alveolar macrophage apoptosis</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2019161119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2019161119</pub-id><pub-id pub-id-type="pmid">35046017</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurens</surname><given-names>C</given-names></name><name><surname>Grundler</surname><given-names>F</given-names></name><name><surname>Damiot</surname><given-names>A</given-names></name><name><surname>Chery</surname><given-names>I</given-names></name><name><surname>Le Maho</surname><given-names>AL</given-names></name><name><surname>Zahariev</surname><given-names>A</given-names></name><name><surname>Le Maho</surname><given-names>Y</given-names></name><name><surname>Bergouignan</surname><given-names>A</given-names></name><name><surname>Gauquelin-Koch</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>C</given-names></name><name><surname>Blanc</surname><given-names>S</given-names></name><name><surname>Wilhelmi de Toledo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Is muscle and protein loss relevant in long-term fasting in healthy men? A prospective trial on physiological adaptations</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><volume>12</volume><fpage>1690</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12766</pub-id><pub-id pub-id-type="pmid">34668663</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>C</given-names></name><name><surname>Gatto</surname><given-names>L</given-names></name><name><surname>Ferro</surname><given-names>M</given-names></name><name><surname>Bruley</surname><given-names>C</given-names></name><name><surname>Burger</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Accounting for the multiple natures of missing values in label-free quantitative proteomics data sets to compare imputation strategies</article-title><source>Journal of Proteome Research</source><volume>15</volume><fpage>1116</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00981</pub-id><pub-id pub-id-type="pmid">26906401</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states</article-title><source>The Journal of Nutrition</source><volume>129</volume><fpage>227S</fpage><lpage>237S</lpage><pub-id pub-id-type="doi">10.1093/jn/129.1.227S</pub-id><pub-id pub-id-type="pmid">9915905</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Zebrafish ism1 is a novel antiviral factor that positively regulates antiviral immune responses</article-title><source>Developmental and Comparative Immunology</source><volume>125</volume><elocation-id>104210</elocation-id><pub-id pub-id-type="doi">10.1016/j.dci.2021.104210</pub-id><pub-id pub-id-type="pmid">34302859</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Tarr</surname><given-names>PT</given-names></name><name><surname>Zhang</surname><given-names>CY</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Boss</surname><given-names>O</given-names></name><name><surname>Michael</surname><given-names>LF</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Isotani</surname><given-names>E</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name><name><surname>Bassel-Duby</surname><given-names>R</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres</article-title><source>Nature</source><volume>418</volume><fpage>797</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/nature00904</pub-id><pub-id pub-id-type="pmid">12181572</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Targeting the PI3K-Akt pathway in human cancer: rationale and promise</article-title><source>Cancer Cell</source><volume>4</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00248-4</pub-id><pub-id pub-id-type="pmid">14585353</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Eif3A regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage</article-title><source>Oncogene</source><volume>41</volume><fpage>2431</fpage><lpage>2443</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02262-5</pub-id><pub-id pub-id-type="pmid">35279705</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mammucari</surname><given-names>C</given-names></name><name><surname>Milan</surname><given-names>G</given-names></name><name><surname>Romanello</surname><given-names>V</given-names></name><name><surname>Masiero</surname><given-names>E</given-names></name><name><surname>Rudolf</surname><given-names>R</given-names></name><name><surname>Del Piccolo</surname><given-names>P</given-names></name><name><surname>Burden</surname><given-names>SJ</given-names></name><name><surname>Di Lisi</surname><given-names>R</given-names></name><name><surname>Sandri</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Sandri</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Foxo3 controls autophagy in skeletal muscle in vivo</article-title><source>Cell Metabolism</source><volume>6</volume><fpage>458</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2007.11.001</pub-id><pub-id pub-id-type="pmid">18054315</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Méchin</surname><given-names>V</given-names></name><name><surname>Damerval</surname><given-names>C</given-names></name><name><surname>Zivy</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Total protein extraction with TCA-acetone: methods in molecular biology</article-title><source>Clifton</source><volume>355</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1385/1-59745-227-0:1</pub-id><pub-id pub-id-type="pmid">17093296</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mina</surname><given-names>AI</given-names></name><name><surname>LeClair</surname><given-names>RA</given-names></name><name><surname>LeClair</surname><given-names>KB</given-names></name><name><surname>Cohen</surname><given-names>DE</given-names></name><name><surname>Lantier</surname><given-names>L</given-names></name><name><surname>Banks</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Calr: a web-based analysis tool for indirect calorimetry experiments</article-title><source>Cell Metabolism</source><volume>28</volume><fpage>656</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.06.019</pub-id><pub-id pub-id-type="pmid">30017358</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minard</surname><given-names>AY</given-names></name><name><surname>Tan</surname><given-names>SX</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Fazakerley</surname><given-names>DJ</given-names></name><name><surname>Domanova</surname><given-names>W</given-names></name><name><surname>Parker</surname><given-names>BL</given-names></name><name><surname>Humphrey</surname><given-names>SJ</given-names></name><name><surname>Jothi</surname><given-names>R</given-names></name><name><surname>Stöckli</surname><given-names>J</given-names></name><name><surname>James</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mtorc1 is a major regulatory node in the FGF21 signaling network in adipocytes</article-title><source>Cell Reports</source><volume>17</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.086</pub-id><pub-id pub-id-type="pmid">27681418</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moro</surname><given-names>T</given-names></name><name><surname>Ebert</surname><given-names>SM</given-names></name><name><surname>Adams</surname><given-names>CM</given-names></name><name><surname>Rasmussen</surname><given-names>BB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Amino acid sensing in skeletal muscle</article-title><source>Trends in Endocrinology and Metabolism</source><volume>27</volume><fpage>796</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2016.06.010</pub-id><pub-id pub-id-type="pmid">27444066</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musarò</surname><given-names>A</given-names></name><name><surname>McCullagh</surname><given-names>KJ</given-names></name><name><surname>Naya</surname><given-names>FJ</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name><name><surname>Rosenthal</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Igf-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1</article-title><source>Nature</source><volume>400</volume><fpage>581</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1038/23060</pub-id><pub-id pub-id-type="pmid">10448862</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Moriya</surname><given-names>Y</given-names></name><name><surname>Kawano</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Takami</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>D</given-names></name><name><surname>Araki</surname><given-names>N</given-names></name><name><surname>Yoshizawa</surname><given-names>AC</given-names></name><name><surname>Tabata</surname><given-names>T</given-names></name><name><surname>Sugiyama</surname><given-names>N</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name><name><surname>Ishihama</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>JPOSTrepo: an international standard data Repository for proteomes</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D1107</fpage><lpage>D1111</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1080</pub-id><pub-id pub-id-type="pmid">27899654</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osório</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct spatiotemporal expression of ISM1 during mouse and chick development</article-title><source>Cell Cycle</source><volume>13</volume><fpage>1571</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.4161/cc.28494</pub-id><pub-id pub-id-type="pmid">24675886</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallafacchina</surname><given-names>G</given-names></name><name><surname>Calabria</surname><given-names>E</given-names></name><name><surname>Serrano</surname><given-names>AL</given-names></name><name><surname>Kalhovde</surname><given-names>JM</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification</article-title><source>PNAS</source><volume>99</volume><fpage>9213</fpage><lpage>9218</lpage><pub-id pub-id-type="doi">10.1073/pnas.142166599</pub-id><pub-id pub-id-type="pmid">12084817</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>A</given-names></name><name><surname>Lacour</surname><given-names>F</given-names></name><name><surname>Giordani</surname><given-names>L</given-names></name><name><surname>Colnot</surname><given-names>S</given-names></name><name><surname>Maire</surname><given-names>P</given-names></name><name><surname>Le Grand</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Apc is required for muscle stem cell proliferation and skeletal muscle tissue repair</article-title><source>The Journal of Cell Biology</source><volume>210</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1083/jcb.201501053</pub-id><pub-id pub-id-type="pmid">26304725</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Strotmeyer</surname><given-names>ES</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Broudeau</surname><given-names>R</given-names></name><name><surname>Kammerer</surname><given-names>C</given-names></name><name><surname>de Rekeneire</surname><given-names>N</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Schwartz</surname><given-names>AV</given-names></name><name><surname>Tylavsky</surname><given-names>FA</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><collab>Health, Aging, and Body Composition Study</collab></person-group><year iso-8601-date="2007">2007</year><article-title>Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study</article-title><source>Diabetes Care</source><volume>30</volume><fpage>1507</fpage><lpage>1512</lpage><pub-id pub-id-type="doi">10.2337/dc06-2537</pub-id><pub-id pub-id-type="pmid">17363749</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pera</surname><given-names>EM</given-names></name><name><surname>Kim</surname><given-names>JI</given-names></name><name><surname>Martinez</surname><given-names>SL</given-names></name><name><surname>Brechner</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>Wessely</surname><given-names>O</given-names></name><name><surname>De Robertis</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Isthmin is a novel secreted protein expressed as part of the FGF-8 synexpression group in the <italic>Xenopus</italic> midbrain-hindbrain organizer</article-title><source>Mechanisms of Development</source><volume>116</volume><fpage>169</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/s0925-4773(02)00123-5</pub-id><pub-id pub-id-type="pmid">12128218</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>BD</given-names></name><name><surname>Caldow</surname><given-names>MK</given-names></name><name><surname>Brennan-Speranza</surname><given-names>TC</given-names></name><name><surname>Sbaraglia</surname><given-names>M</given-names></name><name><surname>Jerums</surname><given-names>G</given-names></name><name><surname>Garnham</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Levinger</surname><given-names>P</given-names></name><name><surname>Asrar Ul Haq</surname><given-names>M</given-names></name><name><surname>Hare</surname><given-names>DL</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>Levinger</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Muscle atrophy in patients with type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise</article-title><source>Exercise Immunology Review</source><volume>22</volume><fpage>94</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">26859514</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>MD</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Choksi</surname><given-names>P</given-names></name><name><surname>Markides</surname><given-names>KS</given-names></name><name><surname>Al Snih</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Muscle weakness thresholds for prediction of diabetes in adults</article-title><source>Sports Medicine</source><volume>46</volume><fpage>619</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1007/s40279-015-0463-z</pub-id><pub-id pub-id-type="pmid">26744337</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>ET</given-names></name><name><surname>Morimoto</surname><given-names>RI</given-names></name><name><surname>Dillin</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>JW</given-names></name><name><surname>Balch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Biological and chemical approaches to diseases of proteostasis deficiency</article-title><source>Annual Review of Biochemistry</source><volume>78</volume><fpage>959</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.052308.114844</pub-id><pub-id pub-id-type="pmid">19298183</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risson</surname><given-names>V</given-names></name><name><surname>Mazelin</surname><given-names>L</given-names></name><name><surname>Roceri</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>H</given-names></name><name><surname>Moncollin</surname><given-names>V</given-names></name><name><surname>Corneloup</surname><given-names>C</given-names></name><name><surname>Richard-Bulteau</surname><given-names>H</given-names></name><name><surname>Vignaud</surname><given-names>A</given-names></name><name><surname>Baas</surname><given-names>D</given-names></name><name><surname>Defour</surname><given-names>A</given-names></name><name><surname>Freyssenet</surname><given-names>D</given-names></name><name><surname>Tanti</surname><given-names>JF</given-names></name><name><surname>Le-Marchand-Brustel</surname><given-names>Y</given-names></name><name><surname>Ferrier</surname><given-names>B</given-names></name><name><surname>Conjard-Duplany</surname><given-names>A</given-names></name><name><surname>Romanino</surname><given-names>K</given-names></name><name><surname>Bauché</surname><given-names>S</given-names></name><name><surname>Hantaï</surname><given-names>D</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Kozma</surname><given-names>SC</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Rüegg</surname><given-names>MA</given-names></name><name><surname>Ferry</surname><given-names>A</given-names></name><name><surname>Pende</surname><given-names>M</given-names></name><name><surname>Bigard</surname><given-names>X</given-names></name><name><surname>Koulmann</surname><given-names>N</given-names></name><name><surname>Schaeffer</surname><given-names>L</given-names></name><name><surname>Gangloff</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy</article-title><source>The Journal of Cell Biology</source><volume>187</volume><fpage>859</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1083/jcb.200903131</pub-id><pub-id pub-id-type="pmid">20008564</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodgers</surname><given-names>JT</given-names></name><name><surname>Schroeder</surname><given-names>MD</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Rando</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hgfa is an injury-regulated systemic factor that induces the transition of stem cells into galert</article-title><source>Cell Reports</source><volume>19</volume><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.03.066</pub-id><pub-id pub-id-type="pmid">28423312</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roubenoff</surname><given-names>R</given-names></name><name><surname>Castaneda</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Sarcopenia-understanding the dynamics of aging muscle</article-title><source>JAMA</source><volume>286</volume><fpage>1230</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1001/jama.286.10.1230</pub-id><pub-id pub-id-type="pmid">11559270</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rui</surname><given-names>L</given-names></name><name><surname>Aguirre</surname><given-names>V</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Corbould</surname><given-names>A</given-names></name><name><surname>Dunaif</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Insulin/Igf-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways</article-title><source>The Journal of Clinical Investigation</source><volume>107</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1172/JCI10934</pub-id><pub-id pub-id-type="pmid">11160134</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Ruiz-Ojeda</surname><given-names>FJ</given-names></name><name><surname>Anguita-Ruiz</surname><given-names>A</given-names></name><name><surname>Rico</surname><given-names>MC</given-names></name><name><surname>Leis</surname><given-names>R</given-names></name><name><surname>Bueno</surname><given-names>G</given-names></name><name><surname>Gil-Campos</surname><given-names>M</given-names></name><name><surname>Gil</surname><given-names>Á</given-names></name><name><surname>Aguilera</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Serum Levels of the Novel Adipokine Isthmin-1 Are Associated with Obesity in Pubertal Boys</article-title><source>medRxiv</source><pub-id pub-id-type="doi">10.1101/2022.03.02.22271664</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandri</surname><given-names>M</given-names></name><name><surname>Sandri</surname><given-names>C</given-names></name><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Skurk</surname><given-names>C</given-names></name><name><surname>Calabria</surname><given-names>E</given-names></name><name><surname>Picard</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy</article-title><source>Cell</source><volume>117</volume><fpage>399</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(04)00400-3</pub-id><pub-id pub-id-type="pmid">15109499</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scanga</surname><given-names>SE</given-names></name><name><surname>Ruel</surname><given-names>L</given-names></name><name><surname>Binari</surname><given-names>RC</given-names></name><name><surname>Snow</surname><given-names>B</given-names></name><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Bouchard</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Calvieri</surname><given-names>B</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Manoukian</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The conserved PI3 ’ K/PTEN/akt signaling pathway regulates both cell size and survival in <italic>Drosophila</italic></article-title><source>Oncogene</source><volume>19</volume><fpage>3971</fpage><lpage>3977</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203739</pub-id><pub-id pub-id-type="pmid">10962553</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>EK</given-names></name><name><surname>Clavarino</surname><given-names>G</given-names></name><name><surname>Ceppi</surname><given-names>M</given-names></name><name><surname>Pierre</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sunset, a nonradioactive method to monitor protein synthesis</article-title><source>Nature Methods</source><volume>6</volume><fpage>275</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1314</pub-id><pub-id pub-id-type="pmid">19305406</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH image to imagej: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Rothman</surname><given-names>DL</given-names></name><name><surname>Jue</surname><given-names>T</given-names></name><name><surname>Stein</surname><given-names>P</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name><name><surname>Shulman</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy</article-title><source>The New England Journal of Medicine</source><volume>322</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1056/NEJM199001253220403</pub-id><pub-id pub-id-type="pmid">2403659</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S</given-names></name><name><surname>Temu</surname><given-names>T</given-names></name><name><surname>Cox</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The maxquant computational platform for mass spectrometry-based shotgun proteomics</article-title><source>Nature Protocols</source><volume>11</volume><fpage>2301</fpage><lpage>2319</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.136</pub-id><pub-id pub-id-type="pmid">27809316</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname><given-names>M</given-names></name><name><surname>Karlsson</surname><given-names>MJ</given-names></name><name><surname>Hober</surname><given-names>A</given-names></name><name><surname>Svensson</surname><given-names>A-S</given-names></name><name><surname>Scheffel</surname><given-names>J</given-names></name><name><surname>Kotol</surname><given-names>D</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Tebani</surname><given-names>A</given-names></name><name><surname>Strandberg</surname><given-names>L</given-names></name><name><surname>Edfors</surname><given-names>F</given-names></name><name><surname>Sjöstedt</surname><given-names>E</given-names></name><name><surname>Mulder</surname><given-names>J</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Berling</surname><given-names>A</given-names></name><name><surname>Ekblad</surname><given-names>S</given-names></name><name><surname>Dannemeyer</surname><given-names>M</given-names></name><name><surname>Kanje</surname><given-names>S</given-names></name><name><surname>Rockberg</surname><given-names>J</given-names></name><name><surname>Lundqvist</surname><given-names>M</given-names></name><name><surname>Malm</surname><given-names>M</given-names></name><name><surname>Volk</surname><given-names>A-L</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Månberg</surname><given-names>A</given-names></name><name><surname>Dodig-Crnkovic</surname><given-names>T</given-names></name><name><surname>Pin</surname><given-names>E</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>von Feilitzen</surname><given-names>K</given-names></name><name><surname>Häussler</surname><given-names>RS</given-names></name><name><surname>Hong</surname><given-names>M-G</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Ponten</surname><given-names>F</given-names></name><name><surname>Katona</surname><given-names>B</given-names></name><name><surname>Vuu</surname><given-names>J</given-names></name><name><surname>Lindström</surname><given-names>E</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Ayoglu</surname><given-names>B</given-names></name><name><surname>Mahdessian</surname><given-names>D</given-names></name><name><surname>Sullivan</surname><given-names>D</given-names></name><name><surname>Thul</surname><given-names>P</given-names></name><name><surname>Danielsson</surname><given-names>F</given-names></name><name><surname>Stadler</surname><given-names>C</given-names></name><name><surname>Lundberg</surname><given-names>E</given-names></name><name><surname>Bergström</surname><given-names>G</given-names></name><name><surname>Gummesson</surname><given-names>A</given-names></name><name><surname>Voldborg</surname><given-names>BG</given-names></name><name><surname>Tegel</surname><given-names>H</given-names></name><name><surname>Hober</surname><given-names>S</given-names></name><name><surname>Forsström</surname><given-names>B</given-names></name><name><surname>Schwenk</surname><given-names>JM</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Sivertsson</surname><given-names>Å</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The human secretome</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaaz0274</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaz0274</pub-id><pub-id pub-id-type="pmid">31772123</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>SH</given-names></name><name><surname>Frigerio</surname><given-names>F</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Joaquin</surname><given-names>M</given-names></name><name><surname>Sticker</surname><given-names>M</given-names></name><name><surname>Fumagalli</surname><given-names>S</given-names></name><name><surname>Allegrini</surname><given-names>PR</given-names></name><name><surname>Kozma</surname><given-names>SC</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity</article-title><source>Nature</source><volume>431</volume><fpage>200</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/nature02866</pub-id><pub-id pub-id-type="pmid">15306821</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valle-Rios</surname><given-names>R</given-names></name><name><surname>Maravillas-Montero</surname><given-names>JL</given-names></name><name><surname>Burkhardt</surname><given-names>AM</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Buhren</surname><given-names>BA</given-names></name><name><surname>Homey</surname><given-names>B</given-names></name><name><surname>Gerber</surname><given-names>PA</given-names></name><name><surname>Robinson</surname><given-names>O</given-names></name><name><surname>Hevezi</surname><given-names>P</given-names></name><name><surname>Zlotnik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Isthmin 1 is a secreted protein expressed in skin, mucosal tissues, and NK, NKT, and Th17 cells</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>34</volume><fpage>795</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1089/jir.2013.0137</pub-id><pub-id pub-id-type="pmid">24956034</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ooijen</surname><given-names>MP</given-names></name><name><surname>Jong</surname><given-names>VL</given-names></name><name><surname>Eijkemans</surname><given-names>MJC</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Andeweg</surname><given-names>AC</given-names></name><name><surname>Binai</surname><given-names>NA</given-names></name><name><surname>van den Ham</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Identification of differentially expressed peptides in high-throughput proteomics data</article-title><source>Briefings in Bioinformatics</source><volume>19</volume><fpage>971</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1093/bib/bbx031</pub-id><pub-id pub-id-type="pmid">28369175</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velloso</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulation of muscle mass by growth hormone and IGF-I</article-title><source>British Journal of Pharmacology</source><volume>154</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.153</pub-id><pub-id pub-id-type="pmid">18500379</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>EM</given-names></name><name><surname>Rotwein</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Selective control of skeletal muscle differentiation by Akt1</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>5106</fpage><lpage>5110</lpage><pub-id pub-id-type="doi">10.1074/jbc.C600315200</pub-id><pub-id pub-id-type="pmid">17218321</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Adelmant</surname><given-names>G</given-names></name><name><surname>Mootha</surname><given-names>V</given-names></name><name><surname>Troy</surname><given-names>A</given-names></name><name><surname>Cinti</surname><given-names>S</given-names></name><name><surname>Lowell</surname><given-names>B</given-names></name><name><surname>Scarpulla</surname><given-names>RC</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1</article-title><source>Cell</source><volume>98</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80611-X</pub-id><pub-id pub-id-type="pmid">10412986</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Shao</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Effect of ISM1 on the immune microenvironment and epithelial-mesenchymal transition in colorectal cancer</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>681240</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.681240</pub-id><pub-id pub-id-type="pmid">34350177</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yenush</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The IRS-signalling system during insulin and cytokine action</article-title><source>BioEssays</source><volume>19</volume><fpage>491</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1002/bies.950190608</pub-id><pub-id pub-id-type="pmid">9204766</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>X</given-names></name><name><surname>Schunter</surname><given-names>A</given-names></name><name><surname>Hummon</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparing multistep immobilized metal affinity chromatography and multistep TiO2 methods for phosphopeptide enrichment</article-title><source>Analytical Chemistry</source><volume>87</volume><fpage>8837</fpage><lpage>8844</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.5b01833</pub-id><pub-id pub-id-type="pmid">26237447</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Hadden</surname><given-names>TJ</given-names></name><name><surname>Rishi</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Akt, FoxO and regulation of apoptosis</article-title><source>Biochimica et Biophysica Acta</source><volume>1813</volume><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.03.010</pub-id><pub-id pub-id-type="pmid">21440011</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Smits</surname><given-names>AH</given-names></name><name><surname>van Tilburg</surname><given-names>GB</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Proteome-Wide identification of ubiquitin interactions using ubia-MS</article-title><source>Nature Protocols</source><volume>13</volume><fpage>530</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.147</pub-id><pub-id pub-id-type="pmid">29446774</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Svensson</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Regulation of energy metabolism by receptor tyrosine kinase ligands</article-title><source>Frontiers in Physiology</source><volume>11</volume><elocation-id>354</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2020.00354</pub-id><pub-id pub-id-type="pmid">32372975</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Specific phosphopeptide enrichment with immobilized titanium ion affinity chromatography adsorbent for phosphoproteome analysis</article-title><source>Journal of Proteome Research</source><volume>7</volume><fpage>3957</fpage><lpage>3967</lpage><pub-id pub-id-type="doi">10.1021/pr800223m</pub-id><pub-id pub-id-type="pmid">18630941</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Benge</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fgf-Receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway</article-title><source>Cell Research</source><volume>19</volume><fpage>1165</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1038/cr.2009.95</pub-id><pub-id pub-id-type="pmid">19652666</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Cat# 000664; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:IMSR_JAX:000664">IMSR_JAX:000664</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J Ism1 whole-body knockout</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Jiang et al., 2021</xref></td><td align="left" valign="bottom">Cat# 036776</td><td align="left" valign="bottom">Generated from C57BL/6J-Ism1em1Kajs/J</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C2C12</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1772; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0188">CVCL_0188</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="char" char="hyphen" valign="bottom">3T3-F442A</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# 00070654; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0122">CVCL_0122</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">Expi293F</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat#: A14527; RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_D615">:CVCL_D615</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p-AKT (Ser473) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 4060; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2315049">AB_2315049</ext-link></td><td align="char" char="." valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Akt (pan) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 4691; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_915783">AB_915783</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p-S6 ribosomal protein (Ser235/236) (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2211; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331679">AB_331679</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-S6 ribosomal protein (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2217, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331355">AB_331355</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p-mTOR (Ser2448) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 5536; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10691552">AB_10691552</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mTOR (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2983; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2105622">AB_2105622</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-beta actin [AC-15] (HRP) (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# AB49900; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_867494">AB_867494</ext-link></td><td align="char" char="." valign="bottom">(1:25,000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Antibody cocktail:<break/>OXPHOS Rodent WB Antibody Cocktail (mouse monoclonal)</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 45-8099; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2533835">AB_2533835</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-phospho-IRS-1 (Ser307) antibody (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2381; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330342">AB_330342</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-IRS-1 antibody (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 3407; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2127860">AB_2127860</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-alpha tubulin antibody (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab4074; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2288001">AB_2288001</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p27 Kip1 antibody (SX53G8.5) (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 3698; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2077832">AB_2077832</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgG HRP linked Ab (rabbit polyclonal)</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# NA934; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2722659">AB_2722659</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgG HRP linked Ab (mouse monoclonal)</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# NA931; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_772210">AB_772210</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-laminin B2 antibody, clone A5 (rat monoclonal)</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# 05-206; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_309655">AB_309655</ext-link></td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-rat IgG secondary antibody, Alexa Fluor 594 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A11007; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10561522">AB_10561522</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh1_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCGAATCGAGGCTCAGAACAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh1_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GTAGTTCCGCCTTCGGTCTTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh2_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AAGTGACTGTGAAAACAGAAGC</named-content><named-content content-type="sequence">A</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh2_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GCAGCCATTTGTAAGGGTTGAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh4_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGAAAAGACGAAGCAGCGAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh4_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AGAGAGCGGGACTCCTTCTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh7_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ACTGTCAACACTAAGAGGGTCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Myh7_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGGATGATTTGATCTTCCAGGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ppargc1a_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TATGGAGTGACATAGAGTGTGCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ppargc1a_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CCACTTCAATCCACCCAGAAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo1_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCAGGCCGGAGTTTAACC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo1_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GTTGCTCATAAAGTCGGTGCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo3_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CTGGGGGAACCTGTCCTATG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo3_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCATTCTGAACGCGCATGAAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo4_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GGTGCCCTACTTCAAGGACA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Foxo4_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">AGCTTGCTGCTGCTATCCAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cdkn1b_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCAAACGTGAGAGTGTCTAACG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Cdkn1b_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CCGGGCCGAAGAGATTTCTG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Eif4ebp1_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">GGGGACTACAGCACCACTC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Eif4ebp1_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CTCATCGCTGGTAGGGCTA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ctsl_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TATCCCTCAGCAAGAGAAAGCCCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Ctsl_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCCTTCATAGCCATAGCCCACCAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Fbxo30_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">TCGTGGAATGGTAATCTTGC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Fbxo30_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CCTCCCGTTTCTCTATCACG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">UbC_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">CGTCGAGCCCAGTGTTACCACC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">UbC_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primer</td><td align="left" valign="bottom"><named-content content-type="sequence">ACCTCCCCCATCACACCCAAGA</named-content></td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Mouse recombinant Ism1-his protein</td><td align="left" valign="bottom">This paper and PMID:34348115</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant mouse IGF-I/IGF-1 protein</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# 791-MG-050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Mouse Ism1 with C-terminal Myc-6X-his tag</td><td align="left" valign="bottom">Addgene and PMID:34348115</td><td align="left" valign="bottom">Cat# 173046; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_173046">Addgene_173046</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Nuclear Cytoplasmic Extraction Reagent kit</td><td align="left" valign="bottom">Pierce</td><td align="left" valign="bottom">Cat# 78833</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bovine serum albumin</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# A7906; CAS:9048-46-8</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rapamycin</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9904</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2× SYBR Green qPCR master mix</td><td align="left" valign="bottom">Bimake</td><td align="left" valign="bottom">Cat# B21203</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trizol</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 15-596-026</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">High-capacity cDNA reverse transcription kit</td><td align="left" valign="bottom">Biosystems</td><td align="left" valign="bottom">Cat# 4368814</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMEM/F12 + GlutaMAX</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 10565-042</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMEM high glucose</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# D6429</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trypsin/EDTA 0.25%</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 25200-056</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin/streptomycin</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 15140-122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PBS</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 10010-023</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Trypan Blue Stain (0.4%)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# T10282</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hoechst</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 33342</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Immobilon Crescendo Western HRP substrate</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Catt# WBLUR0500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SuperSignal West Femto HRP substrate</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# 34095</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SeeBlue Plus2 prestained standard</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# LC5925</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RIPA buffer (10×)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9806S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NuPAGE LDS sample buffer (4×)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# NP0007</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-Mercaptoethanol</td><td align="left" valign="bottom">Fisher Chemical</td><td align="left" valign="bottom">Cat# O3446I</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">PhosSTOP</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 04906837001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cOmplete Tablets</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 04693124001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-[<sup>35</sup>S]-Methionine</td><td align="left" valign="bottom">PerkinElmer</td><td align="left" valign="bottom">NEG009L005MC</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib62">Schneider et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_003070">SCR_003070</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism version 8.0</td><td align="left" valign="bottom">GraphPad Software, San Diego, CA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">http://www.graphpad.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Adobe Illustrator</td><td align="left" valign="bottom">Adobe Systems</td><td align="left" valign="bottom">RRID<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_010279">:SCR_010279</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">RStudio</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://rstudio.com/">https://rstudio.com/</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000432">SCR_000432</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80014.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.19.492758" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.19.492758"/></front-stub><body><p>This article will be of interest to those who study integrated physiology by which muscle size, strength, and metabolism are regulated. Effects of the protein Ism1, which is released by adipocytes and immune cells, on the phosphoproteome were compared and contrasted to those of insulin revealing overlapping though distinct signaling pathways. Ism1 was also shown to determine skeletal muscle size and strength. These data describe a new humoral linkage between fat and skeletal muscle that should have broad implications.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80014.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Cardozo</surname><given-names>Christopher</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Graham</surname><given-names>Zachary</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.19.492758">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.19.492758v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Phosphoproteomic mapping reveals distinct signaling actions and activation of protein synthesis and muscle hypertrophy by Isthmin-1&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Christopher Cardozo as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Mone Zaidi as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Zachary Graham (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Please rephrase conclusions regarding the effects of the knockout on myofiber size to present a more cautious interpretation of the data.</p><p>2) Please carefully consider the remaining comments from each of the three reviewers and revise the manuscript to address them.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. A supplemental table showing results ranked using some system should accompany Figure 2P.</p><p>2. Figure 1A and corresponding text in legend, results, and methods. It sounds like 6 different samples were pooled, after which the pooled cells were divided into two technical replicates for mass spec. Please revise the text to more clearly reflect what was done.</p><p>3. Replotting bar graphs to show individual data points should be performed.</p><p>4. Please discuss briefly the fact that all studies were done with male mice as a limitation of the experiments.</p><p>5. Line 558 – please indicate how many fibers (approximately) were measured for each muscle.</p><p>6. Line 565 – please specify the type of chow – One assumes this was the same feed animals eat normally.</p><p>7. Line 566 – please specify how long measurements were recorded.</p><p>8. Line 569 – Please specify the type of grip test used: wire, grid, 2-paw, 4-paw. Please indicate the number of trials used and, if appropriate, how data from multiple trials were handled.</p><p>9. Line 594 – please indicate the approximate passage number at the time experiments were performed if this is known.</p><p>Suggestions:</p><p>Line 116 – specify the Akt phosphorylation site in the text for ease of reading.</p><p>Including a few literature citations justifying the choice of statistics for the proteomics analysis would improve the manuscript.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>I congratulate the authors for their hard work and innovative study. While there is some enthusiasm for this novel mechanism regulating aspects of muscle health and function, there are some concerns addressed below. I hope the authors do not find the following as negative critiques but rather supportive feedback as the underlying mechanism is quite interesting.</p><p>Major limitations</p><p>– The varying number of animals per study is kind of confusing, as some activity/metabolic cage data have 4 animals (Figure 4A/B), some molecular work has 3 (Figure 5E) or 5 animals (Figure 5G) grip strength has 15 (Figure 4G), but body weight data only has 3 (Figure 4B). It may just be the way the data are worded and presented. Individual data points on the bar charts would clear this up immediately. In Figure 4 for example, n=3/group but then it is reported that the experiment was repeated using two independent cohorts of mice (line 317). So does n=6? Additionally, methods state animal experiments were sex- and age-matched but only used male mice (line 498). If only male mice were used, what is the justification for excluding female mice from these studies?</p><p>– Having only 3 mice per experiment highlights difficulties in interpreting myofiber data. No change in muscle weight weights but myofiber atrophy of only the quad. However, the gastrocnemius fiber size increases by ~20% while the quadriceps has a substantial reduction in fiber size. I don't think the conclusion in line 302 can be interpreted from this data. Ism1 leads to reductions in quad fiber size, yes, but not other muscles. What is unique about the quad for Ism1? Or upper limb function with reduced grip strength?</p><p>– Confirming Ism1 doesn't alter canonical IRS phosphorylation sites in your animal model would be very useful. Since Akt S473 is an mTOR target and the cell work shows Ism1-induced protein synthesis is dependent on mTOR, Ism1-KO validation of normal IRS phosphorylation would highlight the distinct nature of Ism1.</p><p>Moderate limitations</p><p>– While fully understanding the limitations of using cells and the necessity of pooling to get sufficient yield for phosphoproteomics, I have some modest concerns regarding the complete lack of signal in some samples for 2B/E/G. Since phosphorylation state has important biological differences, being completely dephosphorylated in the pooled sample compared to another can have major implications in interpretation. For 2E for example, is TSC2 S1806 completely dephosphorylated by Ism1 or does it have no effect compared to BSA? Regardless of whether this occurred due to the normalization process and is something like a scaling error, some justification for including these and assuming the mean is an appropriate value would be appreciated, even for these early exploratory data.</p><p>– Figure 4. Myofiber atrophy is a primary way muscles may lose their mass but also global KO of Ism1 may alter myofiber number, which with the effects of Ism1 on myoblasts, suggests potential developmental roles. Lastly, while the quadriceps/TA/GST is perfectly representative muscle groups to study, they are largely fast-twitch, heavily type IIx/b muscles. Investigations into the soleus or other oxidative muscle would provide information regarding fiber type specificity for mechanisms of action.</p><p>– Line 324 Ism1 causes quad myofiber atrophy, not muscle atrophy. And if the marker is myofiber atrophy in the quad, then a 50% reduction in myofiber size as shown in 4F should be considered severe atrophy, not mild.</p><p>– Please confirm body mass for 8 wk old animals used for 4B as 30 g would be quite unexpected for an 8 wk old male mouse in my experience.</p><p>– No catabolic cell signaling was investigated. While gene markers are understandable and perfectly reasonable, protein level examination of Foxo phosphorylation or other marker associated with muscle atrophy would strongly complement the pAkt/mTOR/S6 data.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Analysis of Ism1 KO mice revealed a decrease in muscle size (muscle atrophy), but it is unclear whether Ism1 causes muscle hypertrophy. The title and discussion may be overstating somewhat, so I think it is better to reorganize what can be stated from the data.</p><p>Since the KO mice used by the author lack Ism1 systemically from birth, whether the decrease in muscle size results from its action on skeletal muscle is unclear. Is there a possibility of a reduction in growth?</p><p>Quantification of muscle size is one of the most important data in this study. It was difficult to distinguish the muscle size difference between control and Ism1 KO mice in the photo shown in Figure 4D. The muscle size was quantified using 2-4 photographs taken with a 20× objective lens, but there is concern about whether this is sufficient for accurate measurement since the muscle size differs depending on the region and muscle fiber type. In addition, it is recommended to stain the periphery of cells with laminin or dystrophin to quantify muscle size.</p><p>I am concerned that the number of samples is small overall. I have never done phosphoproteomics, but I am unsure whether n = 2 is suitable for statistical analysis.</p><p>Line 334-338: Myh 1, 2, 4, and 7 are muscle fiber type markers rather than differentiation markers, so it should be mentioned whether the muscle fiber type has changed.</p><p>Line 381: The word &quot;muscle function&quot; is vague, so I think it would be better to rewrite it as a more specific term such as &quot;muscle strength.&quot;</p><p>Line 381: No data is shown that suggests lsm1 is a &quot;circulating&quot; regulator.</p><p>Line 378-38: The same sentence is duplicated.</p><p>Line 429: &quot;Ism1-induced muscle hypertrophy&quot; is not shown in the data. To state this, it would be necessary to perform experiments in which Ism1 is administered or overexpressed.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.80014.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Please rephrase conclusions regarding the effects of the knockout on myofiber size to present a more cautious interpretation of the data.</p></disp-quote><p>We have rephrased the conclusions to describe that Ism1 deficiency causes myofiber atrophy instead of muscle atrophy. We have also added additional sections to discuss the limitations of our study in that only one sex was examined.</p><disp-quote content-type="editor-comment"><p>2) Please carefully consider the remaining comments from each of the three reviewers and revise the manuscript to address them.</p></disp-quote><p>We thank the reviewers for their comments and suggestions. Major changes include adding justification for phosphoproteomic analysis, adding laminin staining for muscle tissues, assays on catabolic cell signaling, and additional data to support that the muscle fiber phenotype was not associated with changes in general growth. Please see the point-by-point responses below to individual reviewers’ comments.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. A supplemental table showing results ranked using some system should accompany Figure 2P.</p></disp-quote><p>We have added a supplemental table as source data table for Figure 2P (Figure_2_source_data_1) ranked by “Enrichment score”.</p><disp-quote content-type="editor-comment"><p>2. Figure 1A and corresponding text in legend, results, and methods. It sounds like 6 different samples were pooled, after which the pooled cells were divided into two technical replicates for mass spec. Please revise the text to more clearly reflect what was done.</p></disp-quote><p>This is correct. 6 biological replicates per group for the 3 groups (in total 18 samples) were used to reduce cell-to-cell variability. We have now revised the following statements:</p><p>Figure legend:</p><p>Figure 1A</p><p>Line 621 – “(A) Experimental design of the untargeted phosphoproteomics analysis. 3T3-F442A cells were serum-starved for 16 hours and treated with 100 nM recombinant Ism1 or insulin for 5 minutes (<italic>n</italic> = 6 biological replicates per group were pooled and then divided into <italic>n</italic> = 2 technical replicates).”</p><p>Results:</p><p>Line 118 – “The proteomic experiments were performed in treatment groups of six biological replicates, after which the pooled cells were divided into two technical replicates for the proteomics analysis.”</p><p>Methods:</p><p>Revised:</p><p>Line 403 – “For each treatment group, six biological replicates were pooled into two technical replicates for the phosphoproteomics analysis.”</p><disp-quote content-type="editor-comment"><p>3. Replotting bar graphs to show individual data points should be performed.</p></disp-quote><p>We thank the reviewer for this suggestion. All bar graphs are now revised to show individual data points.</p><disp-quote content-type="editor-comment"><p>4. Please discuss briefly the fact that all studies were done with male mice as a limitation of the experiments.</p></disp-quote><p>Line 390 – In the Methods, “sex- and age-matched, littermate male mice” has been corrected to “age-matched male mice” to clarify that only male mice have been used in this study.</p><p>Line 369 – In the Discussion, we have added the limitation “As this study was conducted in male mice only, it is unknown whether Ism1 deficiency results in a muscle phenotype in female mice. Further studies are required to test whether Ism1 regulates muscle proteostasis in a sex-specific manner.”</p><disp-quote content-type="editor-comment"><p>5. Line 558 – please indicate how many fibers (approximately) were measured for each muscle.</p></disp-quote><p>The following sentence has been added to the Methods section:</p><p>Line 478 – “The quantification of the average muscle fiber area was performed using <italic>n</italic> = 3 independent muscle tissues from each genotype, with 2-4 photos taken from each muscle tissue. ~60-100 myofibers were quantified per image, and average area values were calculated for each image.”</p><p>The following changes have been made to the Figure 4F legend:</p><p>Line 693 – “(WT fed, <italic>n</italic> = 3; <italic>Ism1</italic>-KO fed, <italic>n</italic> = 3; WT fasted, <italic>n</italic> = 3; <italic>Ism1</italic>-KO fasted, <italic>n</italic> = 3; one muscle tissue per mouse, 2-4 images per muscle tissue, ~60-100 myofibers quantified per image).”</p><disp-quote content-type="editor-comment"><p>6. Line 565 – please specify the type of chow – One assumes this was the same feed animals eat normally.</p></disp-quote><p>The standard diet information has been added to Methods:</p><p>Line 388 – “Envigo Teklad Global 18% Protein Rodent Diet 2018”</p><disp-quote content-type="editor-comment"><p>7. Line 566 – please specify how long measurements were recorded.</p></disp-quote><p>The following sentence has been added to the Results section:</p><p>Line 254 – “Ambulatory activity (Figure 5A), respiratory exchange ratio (RER) (Figure 5B), energy expenditure as measured by VO2 consumption (Figure 5C), or food intake (Figure 5D) are indistinguishable between WT and <italic>Ism1</italic>-KO mice when measured over a 48-hour period.”</p><p>The following changes have been made to the Figure 5 legend:</p><p>Line 706 – “Mice were habituated for 24h followed by 48 h recordings of metabolic parameters”.</p><disp-quote content-type="editor-comment"><p>8. Line 569 – Please specify the type of grip test used: wire, grid, 2-paw, 4-paw. Please indicate the number of trials used and, if appropriate, how data from multiple trials were handled.</p></disp-quote><p>Line 492 – We have edited this section in the Methods to “The 2-paw grip strength was measured on a grid with a grip meter. The mice were trained to grasp a horizontal bar while being pulled by their tail. The force (expressed in Newton) was recorded by a sensor. Three trials were combined for analysis.”</p><p>In addition, the following changes have been made to the Figure 4 legend:</p><p>Line 697 – “Grip strength measured by 2-paw muscle force (N) on a grid in WT and <italic>Ism1</italic>-KO mice”.</p><disp-quote content-type="editor-comment"><p>9. Line 594 – please indicate the approximate passage number at the time experiments were performed if this is known.</p></disp-quote><p>The following addition has been made to the Methods section:</p><p>Line 530 – “Cells with passage numbers 6-11 were used for all experiments.”</p><disp-quote content-type="editor-comment"><p>Suggestions:</p><p>Line 116 – specify the Akt phosphorylation site in the text for ease of reading.</p></disp-quote><p>The Akt phosphorylation site “S473” has been specified at all places where appropriate.</p><disp-quote content-type="editor-comment"><p>Including a few literature citations justifying the choice of statistics for the proteomics analysis would improve the manuscript.</p></disp-quote><p>We appreciate the reviewer´s comments on statistics which made us reevaluate our data analyses again. We used the variance stabilization normalization (vsn) of the data, as it has been shown to reduce variation most effectively between technical replicates (https://academic.oup.com/bib/article/19/1/1/2562889). Upon reviewer’s request, we reevaluated our normalization. We found that normalization using log2 yielded a more linear qqplot, but did not reduce variation between technical replicates. Normalization using vsn followed by transformation using log2 resulted in a more linear qqplot while retaining low variation between technical replicates. Thus, and log2 transformation following normalization resulted in normally distributed data whereas vsn normalization alone deviated from normality. We therefore reanalyzed our data using normalization followed by log2 transformation of the data. Log2 transformation of the data did not change the conclusions relating to barplots in the main manuscript, except for minor changes in significance levels in Figure 2. Also, the number of significant phosphosites increased slightly from 202 to 221 for differences between BSA and ISM1 (see adjusted supplementary table “Figure_1_source_data_1”). With the exception of Prrc2c<sup>S899</sup> and Trim56<sup>S450</sup>, all phosphopeptides previously identified as significantly different between BSA and ISM1 were retained.</p><p>The documentation for the DEP package suggests filtering the data before testing for significance. We have not been able to find any benchmark for the use of different filters in the literature. Nevertheless, we reviewed the use of a filter for data preprocessing. The filters suggested at the time of data analysis were: (1) keeping peptides identified in all replicates of one condition or (2) keeping peptides identified in two out of three replicates of at least one condition. As we have a sample size of two, as phosphoproteomics is intrinsically sparse, and as the DEP package was made for proteomics and not specifically phosphoproteomics, we considered that filtering would miss valuable information without increasing number of significant peptides. Applying a filter keeping peptides identified in both replicates of one condition only marginally increased the total number of significant proteins. In conjunction with the reevaluation of our data analyses, we revisited the DEP package pipeline and found that it had been updated with less restrictive filters. We tested different filters and found that removing phosphopeptides present in less than 1/3 of samples yielded the highest number of significant differences after adjustment of multiple testing. Comparing BSA to ISM1 we found 297 significant differences in phosphorylation after filtration (see revised supplementary table “Figure_1_source_data_1”).</p><p>Next, we reevaluated at the GO terms we included for use in figure. We anticipated that including more goterms including the term “TOR” would yield other phosphosites related to mTOR. We therefore included GO terms including “MTORC1” and “MTORC2” besides “TOR” in the description. This yielded 6 more phosphosites related to mTOR uniquely phosphorylated by ISM (see revised figure 1F) and three new phosphosites with significant differences in phosphorylation between Ism1 and insulin. This included Fnip1<sup>S945</sup>, Rps6<sup>S236 &amp; S240</sup>. We replaced Figure 2E-F with the phosphosites for Rps6 which we find is more in relevant given the increased protein synthesis by Ism1.</p><p>In the revised version of the manuscript, we have adjusted the supplementary tables and figures 1E 2A, 2C and 2D to include the added mTOR GO terms. We have changed figures 2I-P using filtering and log2 transformation before imputation and testing. Figure 2E-H were replaced after including additional mTOR GO terms. We have also inserted references in the methods section and changed the text in order to justify the choice of statistics. Importantly, the new analysis results in the same pathways regulated by Ism1.</p><p>The following additions have been made to the Methods section for phosphoproteomics analysis:</p><p>Line 417 – Data acquired on the Orbitrap were searched against a Uniprot <italic>Mus musculus</italic> protein database using TDPortal as previously described (Fornelli et al., 2017; Tyanova et al., 2016). Annotations were extracted from UniProtKB, Gene Ontology (GO), and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Bioinformatics analyses including hierarchical clustering, pathway analysis and annotation enrichment were performed with R v4.1.1 using the DEP package (Zhang et al., 2018) employing filtering of phosphopeptides identified in less than one third of samples, variance stabilization for normalization and maximal reduction of variation between replicates (Huber et al., 2002) and imputation. Tests for significance were based on limma which have a higher sensitivity compared to other algorithms (van Ooijen et al., 2018). To achieve a normal distribution, we log2 transformed data after normalization. Missing data, which due to matrix effects is common to proteomics data were not missing at random, we therefore tested conclusions using the MinProb, man, and QRILC imputation methods appropriate for left censored data (Lazar et al., 2016). For all analyzes, we used the MinProb algorithm as it yielded the lowest number of significant phosphopeptides while retaining large overlap with the two other methods. Since imputation is non-deterministic, in a minority of cases the insulin receptor would not be significantly phosphorylated by insulin. To minimize random effects of imputation we performed 200 permutations of imputations and testing for significance followed by calculation of the median p-value. Using this algorithm, the insulin receptor was consistently found to be phosphorylated by insulin versus BSA, and running the algorithm repeatedly only result in changed to conclusions for 2-3 phosphosites. Pathway enrichment was analyzed using the TopGO package using the classic Kolmogorov-Smirnov test (Alexa A, Rahnenfuhrer J (2022). topGO: Enrichment Analysis for Gene Ontology. R package version 2.48.0.).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>I congratulate the authors for their hard work and innovative study. While there is some enthusiasm for this novel mechanism regulating aspects of muscle health and function, there are some concerns addressed below. I hope the authors do not find the following as negative critiques but rather supportive feedback as the underlying mechanism is quite interesting.</p><p>Major limitations</p><p>– The varying number of animals per study is kind of confusing, as some activity/metabolic cage data have 4 animals (Figure 4A/B), some molecular work has 3 (Figure 5E) or 5 animals (Figure 5G) grip strength has 15 (Figure 4G), but body weight data only has 3 (Figure 4B). It may just be the way the data are worded and presented. Individual data points on the bar charts would clear this up immediately. In Figure 4 for example, n=3/group but then it is reported that the experiment was repeated using two independent cohorts of mice (line 317). So does n=6?</p></disp-quote><p>We thank the reviewer for constructive critique and helpful suggestions. The data were collected from several independent cohorts of animals with consistent results, but the cohorts varied in sample size due to differences in litter sizes. In Figure 4, the results were repeated in two independent cohorts (<italic>n</italic> = 3 each cohort, a total of 6 animals), but data from one representative cohort showing identical results using <italic>n</italic> = 3 are presented. To clarify this, we have now revised all bar graphs to show individual data points.</p><disp-quote content-type="editor-comment"><p>Additionally, methods state animal experiments were sex- and age-matched but only used male mice (line 498). If only male mice were used, what is the justification for excluding female mice from these studies?</p></disp-quote><p>In the Methods line 390, “sex- and age-matched, littermate male mice” has been corrected to “age-matched male mice”.</p><p>In the Discussion line 369, we have added “As this study was conducted in male mice only, it is unknown whether Ism1 deficiency results in the any muscle phenotype in female mice. Further studies are required to test whether the Ism1 regulates muscle proteostasis in a sex-specific manner.”</p><disp-quote content-type="editor-comment"><p>– Having only 3 mice per experiment highlights difficulties in interpreting myofiber data. No change in muscle weight weights but myofiber atrophy of only the quad. However, the gastrocnemius fiber size increases by ~20% while the quadriceps has a substantial reduction in fiber size. I don't think the conclusion in line 302 can be interpreted from this data. Ism1 leads to reductions in quad fiber size, yes, but not other muscles. What is unique about the quad for Ism1? Or upper limb function with reduced grip strength?</p></disp-quote><p>We agree with the reviewer’s assessment that it is unclear why Ism1 loss only affects fiber size at one of the locations. In the Discussion line 359, we have added “Further studies using larger sample sizes are needed to determine whether the effects of Ism1 on muscle proteostasis are specific to fiber types and locations.”</p><p>We have also revised the following sentence in the Results section to only claim what is directly shown.</p><p>Line 245 – “…the <italic>Ism1</italic>-KO mice had impaired muscle force (Figure 4G).”</p><disp-quote content-type="editor-comment"><p>– Confirming Ism1 doesn't alter canonical IRS phosphorylation sites in your animal model would be very useful. Since Akt S473 is an mTOR target and the cell work shows Ism1-induced protein synthesis is dependent on mTOR, Ism1-KO validation of normal IRS phosphorylation would highlight the distinct nature of Ism1.</p></disp-quote><p>We have performed additional experiments to show that in our mouse model, IRS phosphorylation at S318 does not differ between WT and <italic>Ism1</italic>-KO mice.</p><p>In the Results line 291, we have added “<italic>Ism1</italic>-KO mice are indistinguishable from WT mice in the phosphorylation of IRS1 at S307 (<italic>Figure 6 —figure supplement 1</italic>), a canonical IRS phosphorylation site (Rui et al., 2001).”</p><p>In Figure 6 —figure supplement 1, we have added the western blot and quantified protein levels of p-IRS S307 and total IRS1.</p><disp-quote content-type="editor-comment"><p>Moderate limitations</p><p>– While fully understanding the limitations of using cells and the necessity of pooling to get sufficient yield for phosphoproteomics, I have some modest concerns regarding the complete lack of signal in some samples for 2B/E/G. Since phosphorylation state has important biological differences, being completely dephosphorylated in the pooled sample compared to another can have major implications in interpretation. For 2E for example, is TSC2 S1806 completely dephosphorylated by Ism1 or does it have no effect compared to BSA? Regardless of whether this occurred due to the normalization process and is something like a scaling error, some justification for including these and assuming the mean is an appropriate value would be appreciated, even for these early exploratory data.</p></disp-quote><p>We fully understand the reviewer’s concern. Missing values which are common to proteomics data can either mean that a peptide was not identified or that it was masked by other peptides in the search space. Zeros were more abundant for phosphopeptides with a low intensity. Thus, the true biological value is likely to be low. We calculated significance based on imputed values, and this is what the asterisks in the barplots are based upon. In the cases where phosphorylation was displayed as zero (such as for Figure 2B/E/G) the intensity was zero in the raw dataset. MaxQuant which was used to analyze the phosphoproteomics dataset sets a missing value to zero intensity. Therefore, the normalization in the DEP package interprets zero intensity as ´missing´.</p><p>In response to reviewers’ question, we have now better explained the choice of imputation method used for significance testing. We tested algorithms based on the structure of the missing data. Data were not missing at random and left censored (<xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>). We sought to be somewhat conservative in our estimate of significant phosphopeptides. We therefore used the imputation algorithm resulting in the lowest number of significant phosphopeptides retaining a relatively large overlap with the other imputation methods (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Distribution of missing values as a function of log2 transformed intensities.</title><p>Missing values (blue) are more abundant among phosphopeptides with a low intensity across samples. This is referred to as left-censored data.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-sa2-fig1-v2.tif"/></fig><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Overlap between significant phosphopeptides using the missing value imputation algorithms minProb, man and QRILC after running imputation, significance testing and adjustment for multiple testing once for each method.</title><p>Note that numbers may change slightly from run as imputation algorithms are based upon gaussians.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-80014-sa2-fig2-v2.tif"/></fig><p>There is no universally approved method for analyzing missing values. As we do not know the true value of missing points, we chose to set missing values to zero for bar plots, as opposed to an imputed value, or the mean of the average value, which can be misleading. (Please see https://www.rdocumentation.org/packages/imputeLCMD/versions/2.0/topics/impute.MinProb). Nevertheless, we understand that setting the point to zero can be confusing. We have therefore changed the value to n.d. (non-detectable) in bar plots in Figure 2. We have also added that asterisks are based on imputed values. Since we include each measured points and point out missing values in the bar plots, we hope that this is sufficient to clearly interpret the data.</p><p>The following additions have been made to the Methods section for phosphoproteomics analysis:</p><p>Line 444 – “For the proteomics analysis, we calculated the significance based on imputed values. Zeros were more abundant for phosphopeptides with an overall low intensity across the samples. Therefore, the choice of imputation method was based on data missing not at random (MNAR). We tested three imputation methods and continued with the one resulting in the lowest number of significant phosphopeptides retaining a relatively large overlap with other imputation methods. In cases where phosphorylation was displayed as zero, the intensity was zero in the raw dataset.”</p><p>Line 661 – The legend to figure 2 now includes: “Note that, in case of non-detectable phosphopeptides, significance testing was based on imputed values”, and “n.d. = non-detectable”.</p><disp-quote content-type="editor-comment"><p>– Figure 4. Myofiber atrophy is a primary way muscles may lose their mass but also global KO of Ism1 may alter myofiber number, which with the effects of Ism1 on myoblasts, suggests potential developmental roles. Lastly, while the quadriceps/TA/GST is perfectly representative muscle groups to study, they are largely fast-twitch, heavily type IIx/b muscles. Investigations into the soleus or other oxidative muscle would provide information regarding fiber type specificity for mechanisms of action.</p></disp-quote><p>We thank the reviewer for this suggestion. In Figure 4—supplement 2, we have added data from the soleus muscle to show that muscle fiber size and muscle mass were not changed. The figure legend of Figure 4 —figure supplement 2 has been updated accordingly.</p><p>Line 359 – In the Discussion, we have added “Further studies using larger sample sizes are needed to determine whether the effects of Ism1 on muscle proteostasis are specific to fiber types and locations.”</p><disp-quote content-type="editor-comment"><p>– Line 324 Ism1 causes quad myofiber atrophy, not muscle atrophy. And if the marker is myofiber atrophy in the quad, then a 50% reduction in myofiber size as shown in 4F should be considered severe atrophy, not mild.</p></disp-quote><p>We have revised the following sentence:</p><p>Line 251 – “Since <italic>Ism1</italic> ablation causes severe myofiber atrophy, we next investigated…”</p><disp-quote content-type="editor-comment"><p>– Please confirm body mass for 8 wk old animals used for 4B as 30 g would be quite unexpected for an 8 wk old male mouse in my experience.</p></disp-quote><p>We can confirm that the body mass in our 8-week-old male mice is ~30 g. Jax reports an average body weight of 8-week-old 25.0 ± 1.4 g for wildtype male mice. Our WT and <italic>Ism1</italic>-KO mice are generated from in-house breeding, so the body weight may be different from commercially available mice.</p><disp-quote content-type="editor-comment"><p>– No catabolic cell signaling was investigated. While gene markers are understandable and perfectly reasonable, protein level examination of Foxo phosphorylation or other marker associated with muscle atrophy would strongly complement the pAkt/mTOR/S6 data.</p></disp-quote><p>We have now measured the FoxO target p27 (gene <italic>Cdkn1b</italic>) and observe elevated protein levels in the <italic>Ism1</italic>-KO compared to WT mice, in addition to the previous gene expression data (new Figure 6F). This finding is consistent with increased catabolic signaling in the <italic>Ism1</italic>-KO mice. We have moved the previous Figure 6F on ubiquitin expression into Figure 6 —figure supplement 1.</p><p>The Results of this section has been revised to:</p><p>Line 279 – Furthermore, under either fed or fasted conditions, muscles isolated from <italic>Ism1</italic>-KO mice have significantly increased transcript levels of atrophy genes FoxO1 (<italic>Figure 6D</italic>), the FoxO target genes <italic>Cdkn1b</italic>, <italic>Eif4ebp1</italic>, and <italic>Ctsl</italic> (<italic>Figure 6E</italic>), ubiquitin ligase <italic>Fbxo30</italic> compared with WT mice (<italic>Figure 6 —figure supplement 1</italic>), and increased protein levels of FoxO target p27 (<italic>Cdkn1b</italic>) (<italic>Figure 6F</italic>) (Zhang et al., 2011).</p><p>We have added this to the Methods section Western blots and molecular analyses.:</p><p>Line 565 – The cytoplasmic fraction was isolated using a Nuclear Cytoplasmic Extraction Reagent kit (78833, Pierce, Rockford, IL, USA) according to the manufacturer's instructions.</p><p>This reference has been added:</p><p>Line 1105 – Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011 Nov;1813(11):1978-86. doi: 10.1016/j.bbamcr.2011.03.010. Epub 2011 Mar 31. PMID: 21440011.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>Analysis of Ism1 KO mice revealed a decrease in muscle size (muscle atrophy), but it is unclear whether Ism1 causes muscle hypertrophy. The title and discussion may be overstating somewhat, so I think it is better to reorganize what can be stated from the data.</p></disp-quote><p>We agree with the reviewer and have revised the title to:</p><p>Line 1 – “Phosphoproteomic mapping reveals distinct signaling actions and activation of muscle protein synthesis by Isthmin-1”</p><disp-quote content-type="editor-comment"><p>Since the KO mice used by the author lack Ism1 systemically from birth, whether the decrease in muscle size results from its action on skeletal muscle is unclear. Is there a possibility of a reduction in growth?</p></disp-quote><p>We thank the reviewer for this insightful comment. We have measured the femur length in male mice at 10 weeks of age and there is no significant difference from WT mice. Therefore, we do not believe that Ism1 deficiency results in growth reduction. We have added Figure 4 – figure supplement 2, methods, results, and discussion to the revised version of the manuscript.</p><p>Figure Legend:</p><p>Femur length measured in WT and <italic>Ism1</italic>-KO (WT, <italic>n</italic> = 6; <italic>Ism1</italic>-KO, <italic>n</italic> = 5, two-tailed student’s t-test *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001).</p><p>Methods:</p><p>Line 497 – Femur length measurement</p><p>Both left and right femurs from each mouse were carefully dissected, and the length between the distal and proximal ends of the bone was measured with a ruler. The average value of the left and right femurs of each individual mouse was used for data analysis. Statistical significance was calculated using a two-tailed student’s t-test.</p><p>Results:</p><p>Line 242 – “While the heart weights (<italic>Figure 4 —figure supplement 2</italic>), muscle weights (<italic>Figure 4 —figure supplement 2</italic>), femur length (<italic>Figure 4 —figure supplement 2</italic>), or total body weights (<italic>Figure 4B</italic>) of <italic>Ism1</italic>-KO mice were not significantly different from WT, the <italic>Ism1</italic>-KO mice had impaired muscle force (<italic>Figure 4G</italic>).”</p><p>Discussion:</p><p>Line 355 – “Femur length is a basic biometric parameter used to assess longitudinal growth. Femur length and total body weights did not differ between WT and <italic>Ism1</italic>-KO mice, suggesting that the decrease in muscle fiber size is likely not due to growth reduction.”</p><disp-quote content-type="editor-comment"><p>Quantification of muscle size is one of the most important data in this study. It was difficult to distinguish the muscle size difference between control and Ism1 KO mice in the photo shown in Figure 4D. The muscle size was quantified using 2-4 photographs taken with a 20× objective lens, but there is concern about whether this is sufficient for accurate measurement since the muscle size differs depending on the region and muscle fiber type. In addition, it is recommended to stain the periphery of cells with laminin or dystrophin to quantify muscle size.</p></disp-quote><p>We apologize for the lack of clarity. The representative pictures shown in figure 4D were taken with a 40x lens to show ~15 myofibers per image. However, the quantification was done using images taken with a 20× objective lens which contain ~ 60-100 myofibers per photo from a total of 2-4 photographs per muscle (<italic>n</italic> = 3 mice/group), totaling to 360-1200 myofibers per condition which we assessed to be sufficient for accurate quantification.</p><p>We have magnified the previous H and E staining to show muscle fibers more clearly and moved them to the supplementary figure. We have clarified this in the Methods section and in the Figure legend.</p><p>We have also performed laminin staining in the revised Figure 4D to better visualize muscle fibers under fed and fasted conditions in the WT and <italic>Ism1</italic>-KO muscle tissues.</p><p>In the Methods section, we have added methods for Immunofluorescence staining and imaging:</p><p>Line 464 – “Sections from muscles were fixed using 4% PFA, permeabilized using 0.2% Triton X-100 in PBS, blocked using 1% BSA in PBS, and incubated with anti-Laminin antibody (Millipore, clone A5, cat # 05-206, 1:200) and then with AlexaFluor secondary Antibodies (#A11007, Invitrogen, 1:1000). Nuclei were counterstained with Hoechst (#33342, Thermo Fisher, 1:1000). Images were acquired using a confocal microscope (Leica TCS SP8) at 63x.”</p><p>The legends of Figure 4 and Figure 4 —figure supplement 2 have been updated accordingly.</p><disp-quote content-type="editor-comment"><p>I am concerned that the number of samples is small overall. I have never done phosphoproteomics, but I am unsure whether n = 2 is suitable for statistical analysis.</p></disp-quote><p>We thank the reviewer for this important comment and have added additional clarification on how the analysis was done. To calculate the significance, we have used the DEP package that employs limma. We agree that a sample size of two is small. However, there is no lower limit for sample size when using this type of t-test and a sample size of 2 can therefore technically be used. A previous proteomics report indicates that limma accurately estimates significant peptides even at n=2 (van Ooijen et al., 2018). While a larger sample size would be ideal, we do not believe a higher sample size would have changed the results significantly. In many cases signal was completely missing in both replicates of one condition. In such cases, adding another replicate would likely lead to another missing value. Moreover, the number of significant peptides only saturates at a sample size between nine and fifteen. Thus, it is likely that while the number of significant peptides would increase by using a larger sample size, for the significant phosphopeptides identified, our conclusions hold.</p><p>The following statement has been added to the Methods section:</p><p>Line 438 – “To calculate the significance between proteomic samples with a sample size of 2, we used the DEP package. The DEP package employs limma for statistical testing. This package uses the t-test except that the standard errors have been moderated across genes, i.e., shrunk towards a common value, using a simple Bayesian model (van Ooijen et al., 2018). The assumptions for limma are that the data are normally distributed and equal variance between replicates. These assumptions were met after normalization and log2 transformation“.</p><p>The following reference has been added:</p><p>Line 1080 – Michiel P van Ooijen, Victor L Jong, Marinus J C Eijkemans, Albert J R Heck, Arno C Andeweg, Nadine A Binai, Henk-Jan van den Ham, Identification of differentially expressed peptides in high-throughput proteomics data, <italic>Briefings in Bioinformatics</italic>, Volume 19, Issue 5, September 2018, Pages 971–981.</p><disp-quote content-type="editor-comment"><p>Line 334-338: Myh 1, 2, 4, and 7 are muscle fiber type markers rather than differentiation markers, so it should be mentioned whether the muscle fiber type has changed.</p></disp-quote><p>We have revised the following sentence in the Results section to reflect the muscle fiber type changes:</p><p>Line 261 – “General muscle markers, including the myosin heavy chain proteins <italic>Myh1</italic>, <italic>Myh2</italic>, <italic>Myh4</italic>, and <italic>Myh7</italic> were not altered under fed conditions, and only <italic>Myh4</italic> was reduced in the <italic>Ism1</italic>-KO mice under fasted conditions, suggesting that muscle fiber type is largely unaffected by <italic>Ism1</italic> ablation (<italic>Figure 5H</italic>).”</p><disp-quote content-type="editor-comment"><p>Line 381: The word &quot;muscle function&quot; is vague, so I think it would be better to rewrite it as a more specific term such as &quot;muscle strength.&quot;</p></disp-quote><p>We have replaced “muscle function” with “muscle strength” in the following sentence:</p><p>Line 293 – “Taken together, these results demonstrate that Ism1 is an anabolic regulator of protein synthesis and muscle strength by maintaining high Akt activity and protein synthesis in skeletal muscle.”</p><disp-quote content-type="editor-comment"><p>Line 381: No data is shown that suggests lsm1 is a &quot;circulating&quot; regulator.</p></disp-quote><p>Ism1 is known to be present in circulation. However, we have removed the word “circulating” on line 294 as we don’t formally show this in this paper in the context of muscle function.</p><p>A section in the Discussion section discusses Ism1 as a circulating regulator:</p><p>Line 362 – “Circulating levels of human ISM1 using immunoreactive ELISAs have been reported to be in the range of 1-50 ng/ml (Jiang et al., 2021; Ruiz-Ojeda et al., 2022), consistent with mass spectrometry peptide analysis which estimates a circulating Ism1 concentration of 17 ng/ml (Uhlén et al., 2019). The necessary circulating and local Ism1 levels to maintain muscle fiber size or prevent fasting-induced muscle loss remain to be determined.”</p><disp-quote content-type="editor-comment"><p>Line 378-38: The same sentence is duplicated.</p></disp-quote><p>Line 293 – We have removed the duplicated sentence.</p><disp-quote content-type="editor-comment"><p>Line 429: &quot;Ism1-induced muscle hypertrophy&quot; is not shown in the data. To state this, it would be necessary to perform experiments in which Ism1 is administered or overexpressed.</p></disp-quote><p>We have removed the phrase “Ism1-induced muscle hypertrophy” from the following sentence, as we don’t formally show this in this paper:</p><p>Line 313 – “Ism1-induced signaling is not simply an activation of the identical insulin/IGF-1-induced PI3K-Akt pathway.”</p><p>A section in the Discussion discusses the necessity of future studies to test whether Ism1 induces muscle hypertrophy:</p><p>Line 373 – “Long-term studies ought to explore if pharmacological administration of Ism1 systemically or locally into the muscle is sufficient to induce muscle hypertrophy or prevent muscle loss in more severe models of muscle loss.”</p></body></sub-article></article>